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1.1 Oro-intestinal nutrient-sensing 
The gastrointestinal tract (GIT) is the largest endocrine organ in the human body and it represents the 
proxy for communication between the human body and the external environment. The cells of the gut 
epithelium possess a subtle chemosensory system that collect the information about nutrient presence 
and composition in the lumen and activate other systems involved in the regulation of appetite, 
immune response, and gastrointestinal motility. Distress or adaptations in the communication of this 
sensory information may contribute to the development or maintenance of disease (Steensels & 
Depoortere 2018). 
New findings support the existence of a functional continuum along the oro-intestinal tract that 
permanently senses ingested nutrients and non-nutrients to control ingestion, digestion, absorption, 
and the metabolic fate of energy nutrients. Taste buds and cells in the gut epithelium share common 
sensors, express similar hormones and receptors, and are connected to gustatory and vagal afferent 
nerve fibers involved in feeding behaviour (Roper & Chaudhari, 2017). Taste perception can be 
considered as a novel key player participating in the regulation of gut function, likewise specific diets 
or agonists that target these chemosensory signalling pathways may be considered as new therapeutic 
targets to tune adequate physiological processes in the gut, in health and/or disease condition. 
Particularly, taste buds represent the peripheral organs of taste, located mainly in the tongue 
epithelium. They sample the chemical makeup of foods and beverages for nutrient content, 
palatability and potential toxicity. The substantial diversity and redundancy of the molecular receptors 
for these compounds may reflect the importance of identifying nutrients and avoiding chemical 
threats from the environment. The molecular recognition of tastants, which occurs at the apical tips 
of taste bud cells, ultimately results in sensory perceptions (sweet, bitter, fat, umami, salty and sour) 
that guide appetite and trigger physiological processes for absorbing nutrients and adjusting 
metabolism.  
The receptors on the chemo-sensitive apical side of taste bud cells confer specificity to gustatory 
stimuli. Taste receptors come in many types, including several classes of G protein-coupled receptors 
(GPCRs) and ion channels (Roper & Chaudhari, 2017). 
After ingestion of the meal, the gut, will “taste” the macronutrient composition of the meal in order 
to elicit motor and secretory responses to assimilate nutrients. The chemosensory systems involved 
are similar to those present in oral cavity and are present on several cell types in the gut epithelium, 
such as enterocytes, enteroendocrine cells (EECs), tuft cells, Paneth cells, goblet cells, microfold 
cells, and cup cells. The epithelium plays a prominent role in the communication between the lumen, 
sub-epithelium, afferent nerve fibers, and the brain to trigger adaptive responses that affect 
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gastrointestinal function, food intake, glucose metabolism, and immune function (Stenseels & 
Depoortere, 2018). 
Enterocytes are absorptive cells and are the major cell type lining the gut. On the apical side, they 
contain microvilli to enlarge the luminal contact surface and express several transporters that regulate 
the uptake of nutrient metabolites such as sugars, amino acids, and fatty acids (Figure 1a). 
 
Figure 1 chemosensors in (a) enterocytes, (b) enteroendocrine cells of the gastrointestinal epithelium. Nutrients (carbohydrates, 
proteins, and fatty acids) are sensed by different receptors and/or transporters. Abbreviations: AA, amino acid; CaSR, calcium-sensing 
receptor; CD36, cluster of differentiation 36; FATP4, fatty acid transport protein 4; FFAR1/2/3/4, free fatty acid receptor 1/2/3/4; 
GLUT2/5, glucose transporter 2/5; GPR119, G protein–coupled receptor 119; GPRC6A: G protein–coupled receptor family C group 
6 member A; KATP, ATP-sensitive potassium; MCT, monocarboxylate transporter; OLFR78, olfactory receptor 78; PEPT1/2, peptide 
transporter 1/2; SCFA/HCO3 −, short-chain fatty acid bicarbonate exchanger; SGLT1/3, sodium-dependent glucose cotransporter 1/3; 
TAS1R1/2/3, taste 1 receptor family member 1/2/3. (Steensel & Depoortere 2018) 
 
EECs represent the largest endocrine organ in the body. They are scattered throughout the GIT but 
only comprise <1% of the gut epithelium. At least 12 subtypes of EECs secrete a wide range of 
peptides (>20) to affect a number of physiological processes involved in the regulation of food intake 
and gastrointestinal motility (Roder et al., 2014) (Figure 1b).  
EECs and absorptive epithelial cells are characterized by chemosensors that allow the detection of 
nutrient in the intestinal lumen (i.e. nutrient-sensing). ECCs act as chemosensory transducers that 
reply to dietary nutrients and other compounds by triggering the release of regulatory peptides to 
initiate humoral and vagal signalling cascades that convey information to the brain concerning the 
luminal milieu. As a consequence, a wide array of physiological responses, ranging from stimulation 
of gastric, intestinal, and pancreatic secretions to inhibition or stimulation of appetite and food intake, 
are triggered. Thus, intestinal chemosensing can regulate nutrient uptake and gut peptide secretion in 
order to control energy request and whole body metabolism (Stenseel & Depoortere, 2018). 
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Recent evidence suggests that nutrients can also directly interact with the nervous system via a 
neuroepithelial circuit. Moreover, peptide-secreting vesicles in EECs are contained within an axon-
like basal process, called neuropod, that appears to guide the secretion of hormones to neurons 
innervating the small intestine and colon (Bohorquez et al., 2015), mainly serves to monitor the 
metabolic state and to relay hunger and satiety signals (Page et al., 2012). By synapsing with the 
vagus nerve, neuropod cells connect the gut lumen to the brainstem and they can transduce sensory 
stimuli in milliseconds by using glutamate as a neurotransmitter, providing a neuroepithelial circuit 
for fast sensory transduction (Kaelberer et al., 2018). It is hypothesized that the gut-brain neural 
circuit formed by neuropod cells and vagal nodose neurons could lead to: rapid computation of stimuli 
to distinguish their physical (e.g., volume) versus chemical (e.g., calorie) properties; precise sensory 
representation of specific gastrointestinal regions; localized plasticity encoded within the neural 
circuit; and timely vagal efferent feedback to modulate gastrointestinal sensory function (Kaelberer 
et al., 2018). The intestinal chemosensing can regulate the nutrient uptake and gut peptide secretion 
in order to control energy request and whole body metabolism (Janssen & Depoortere, 2013). GPCRs, 
expressed both in the oral cavity and in endocrine cells within the gut mucosa, coordinate the release 
of hormones-like peptides such as: ghrelin, cholecystokinin (CCK), glucagon-like peptide-1 (GLP-
1), and peptide tyrosine-tyrosine (PYY (3–36)) that regulate food intake and glucose homeostasis as 
well as nutrient-sensing in the gut (Steinert et al., 2017). 
Ghrelin secretion is stimulated mainly by neural control levels and is correlated with hunger 
sensations and meal size. Feedback from small-intestinal nutrient sensing inhibits ghrelin secretion 
during and after meals (Steinert et al., 2017). Ghrelin exerts physiological effects on brain, stomach 
and pancreatic β-cells stimulating eating, gastric emptying, inhibiting insulin secretion, respectively 
(Janseen & Depoortere 2013). 
CCK is the best-established GI endocrine satiation signal in humans. CCK may contribute to the 
control of meal-related glycaemia both indirectly, via its effect on gastric emptying delay, and directly 
via control of hepatic glucose production (Steinert et al., 2017).  
GLP-1 contributes to meal-related glycaemic control by stimulating insulin secretion, inhibiting 
glucagon secretion, slowing gastric emptying, and reducing hepatic glucose metabolism. GLP-1 may 
also contribute to glycaemic control in the fasting state. GLP-1, together with glucose-dependent 
insulinotropic polypeptide (GIP), mediates the incretin effect by exerting dose-related, glucose-
dependent insulinotropic effects on β-cells (Steinert et al., 2017). 
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PYY(3–36) is secreted in response to carbohydrates, lipids, and proteins digestion during and after 
meals. PYY may contribute to gastric emptying via the ileal brake mechanism, to the inhibition of 
eating, and to the control of meal-related glycaemia (Steinert et al., 2017). 
 
1.2 Cross-talk between brain and gut: homeostatic/hedonic feeding and GI motility 
 
Metabolic homeostasis is orchestrated in response to nutrient and vagal-dependent gut-initiated 
functions. Specifically, the sensory and motor fibres of the vagus nerve transmit intestinal signals 
to the CNS and exert biological and physiological responses (Waise et al., 2018). 
Feeding control is a tightly regulated process at the brain level, requiring accurate information 
regarding the amount and nutrient content of food ingested into the GIT. Gut nutrient-sensing, 
hormone-derived satiety or hunger signals communicate with the CNS via the vagal afferent system, 
which expresses multiple receptors for orexigenic and anorexigenic peptides (Janseen & Depoortere  
2013). Hormones also modulate mechanosensitive neurons that could potentially affect feeding 
(Kentish &Page 2014). For example, both CCK and leptin increase the firing of vagal afferent fibres 
(which affect feeding) that are also responsive to mechanical distension in rodents (Kentish et al., 
2014). Moreover, 5-HT is secreted from gastric enterochromaffin cells in response to gastric 
distension to provide intake inhibitory signals by activating vagal mechanosensitive neurons, whereas 
ghrelin inhibits gastric tension receptors to lower the mechanosensitivity of the vagal afferent neurons 
(Page et al., 2007). Vagal mechanosensitive afferent activity is also modulated directly by volumetric 
gastrointestinal distention, which plays a pivotal role in controlling food intake behaviour triggering 
satiety or fullness sensations (Figure 2) (Waise et al., 2018). 
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Figure 2. Before a meal, gastrointestinal- derived orexigenic mediators (ghrelin) initiate a hunger drive through the vagal afferent 
system. In response to a meal, nutrient- sensing and volumetric- stretch-sensing mechanisms in the stomach and the intestine trigger 
various signalling pathways within the vagal afferent nerves to regulate appetite and glucose homeostasis via the central nervous 
system. Branch points, where the parent vagal nerves intersect with the downstream neuronal branches, might facilitate the interaction 
of orexigenic and anorexigenic signals, thereby affecting feeding and glucose homeostatic control (Waise et al., 2018). 
 
Extrinsic sensory pathways (vagal, thoracolumbar, lumbosacral, and viscerofugal) terminate in the 
gut and convey mechano- and chemosensory signals to target tissues within and outside the intestine 
to impact physiology and behavior (Brookes et al., 2013). 
In addition, the gut is the only organ that contains its own intrinsic nervous system, the enteric nervous 
system (ENS). The ENS is often referred to as the second brain because it provides local control of 
the gastrointestinal tract and continues to function even when the primary neural connection with the 
vagus nerve is severed. Furthermore, the ENS contains sensory neurons, which are intrinsic primary 
afferent neurons that respond to mechanical and chemical stimuli and regulate the appropriate output 
to muscle and secretory motor neurons (Lasrado et al., 2017).  
Many functions of the digestive system, and functions related to digestion, like satiety, involve both 
enteric innervation and the endocrine system. The ENS is one component of the neural control system 
of the digestive tract, working in concert with the CNS, interacting with both the gut endocrine and 
immune systems as well as having roles in modifying nutrient absorption and maintaining the 
mucosal barrier. In the small and large intestine, the ENS contains full reflex pathways that are 
essential to direct the movements of these parts of the digestive tract and to control fluid movement 
between the gut lumen and body compartments (Steensel & Depoortere, 2018). 
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Central regulation of food intake is a key mechanism contributing to energy homeostasis. Many 
neural circuits that orchestrate feeding behaviour overlap with the brain’s reward circuitry both 
anatomically and functionally. Numerous neural pathways can simultaneously influence food intake 
and reward, controlling homeostatic and hedonic feeding, whereas homeostatic feeding is necessary 
for basic metabolic processes and survival, while hedonic feeding is driven by sensory perception or 
pleasure (Rossi & Stuber, 2017). Despite much progress toward understanding how certain parts of 
the brain contribute to either feeding or reward, questions of motivated behaviour continue to be 
framed in terms of homeostatic feeding (food intake that is necessary to maintain typical body weight 
and metabolic function) or hedonic feeding (food intake driven by sensory perception or pleasure). 
Together, the systems involved in hedonic and homeostatic aspects of feeding provide a means by 
which the nervous system can dynamically coordinate intake of ‘rewarding’ stimuli in order to meet 
metabolic demands and ensure survival (Rossi & Stuber, 2017). 
Nowadays, cognitive reasoning, impulsivity, and executive self-control related to enticing food are 
challenged on a daily basis (Spence et al., 2016). The shift from normal “liking” and “wanting” to 
addictive behaviour has a pivotal role in neural mechanism for disordered eating. Stress-induced 
overeating can be seen as another disorder of reward mechanisms, and reward from comfort food is 
considered an attempt at self-medication to relieve the negative emotion and depressive state 
associated with chronic psychological stress (Berthoud et al., 2017). 
The neural circuits controlling feeding and emotional behaviours are tightly and reciprocally 
connected (Sweeney & Yang, 2017). Since feeding is essential for survival, the brain has evolved 
multiple overlapping mechanisms to assure adequate levels of food intake during changing energy 
demands, involving several feeding centers distributed in the hypothalamus, hindbrain, and limbic 
brain regions conveying emotional information (Morton et al., 2014; Sternson et al., 2013; Schwartz 
& Zeltser, 2013; Williams & Elmquist, 2012). Consistently, feeding and emotions are known to be 
interrelated on a behavioural level (Sweeney & Yang, 2017). For example, psychiatric disorders are 
often associated with changes in feeding behaviour and metabolic disorders including obesity are 
associated with an increased risk for the development of mood and anxiety disorders (Foster et al., 
2017).  
The opioid signaling influences dietary behavior modulating individual ‘wanting’ of foods and 
‘liking’. Opioid peptides bind μ-opioid receptors (MORs) involved in the food reward system by 
attributing a value of enjoyment to the taste of food and play also a key role in modulating food intake. 
MORs are well known to interfere with the mechanisms of regulation of pain. In particular, they are 
the targets of opioids, which act as agonists on MORs to promote analgesia (De Vadder et al., 2013). 
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It is noteworthy that, after the brain, the body site in which MORs are most widely expressed is the 
gastrointestinal area (neurons of the ENS), especially the small intestine, where they have been 
shown to control gut motility (i.e. delayed gastric emptying and slowing of intestinal transit) and 
may influence food intake (Ruscitto et al., 2015). 
Gastrointestinal motility is known to be associated with neurotransmitters such as serotonin, 
dopamine, and γ-aminobutyric acid (GABA). Particularly, biochemical signalling from the GI tract 
to the CNS is mediated by GABA, a primary inhibitory neurotransmitter involved in GABAergic 
signalling process, occurring in the intestinal epithelium. Furthermore, gut microbiota can influence 
CNS activity through the production of molecules that function as local neurotransmitters, including 
serotonin, melatonin, GABA, acetylcholine and histamine as well as affect anxiety-like behaviour, 
responsiveness and activation of the hypothalamic-pituitary-adrenal axis (HPA) (Arneth, 2018). 
Calcium-sensing receptor (CaSR) is also present in the gastrointestinal tract, and is expressed on the 
apical and basolateral membranes of villous and crypt epithelial cells of the small intestine and colon, 
respectively, where it is involved in the regulation of intestinal homeostasis related intestinal 
absorption, secretion and motility. Furthermore, calcium-induced activation of CaSR trigger the 
regeneration of the intestinal barrier, suggesting that CaSR may be a promising target for treating 
intestinal inflammation (Zhang et al., 2015). 
 
1.3 Food-derived bioactive peptides  
Food is a source of bioactive compounds affecting human health. Altogether, public health 
professionals, consumers, food producers are becoming increasingly aware of the rapidly expanding 
body of epidemiological evidence linking the prevalence of diseases, such as obesity, cardiovascular 
disease, diabetes to dietary factors. This has led to an increased interest in the potential health effects 
of food derived bioactive compounds. Dietary proteins (including animals and plants sources) are 
characterized by peptides and amino acids encrypted within the primary structures of precursor 
protein molecule and both may be released either during food processing and/or during GI digestion 
(De Noni et al., 2009). 
The process of GI digestion includes mechanical, chemical and enzymatic steps affecting the release 
of nutrients and promote their absorption. Bioactive peptides (BAPs) are short amino acid sequences 
that come from digestion of dietary protein and exert a measurable biological effect on body functions 
and health (Moller et al., 2008). Several food peptides are known to possess regulatory functions that 
can lead to health benefits as demonstrated mostly through in vitro, cell culture and animal studies. 
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Some dietary peptides show antihypertensive, antioxidant, anti-inflammatory, hypolipidemic, 
anticancer, antidiabetic and antimicrobial properties (Udenigwe & Fogliano, 2017). 
BAPs need to be released from food matrix in the intestinal lumen to exert a biological effect and 
they can reach tissues through systemic circulation. Before this happens, BAPs undergo to hydrolysis 
during small intestinal passage and absorption. The GI tract is able to process a wide range of protein 
sources and the cascade of gastrointestinal proteolytic and peptidolytic enzymes very efficiently 
cleaves proteins into short- and medium-sized peptides as well as free amino acids. The amino acid 
absorption occurs in the form of di- and tripeptides at the apical side of enterocytes mediated by the 
proton-coupled peptide transporter 1 (PEPT1) whereas efflux of intact peptides via the basolateral 
membrane into systemic circulation seems to be negligible (Daniel & Zietek, 2015). Moreover, 
vascular endothelial tissue peptidases and soluble plasma peptidases further contribute to peptide 
hydrolysis, this is the reason why for most peptides the plasma half-life is limited to minutes (Foltz 
et al., 2010). 
However, some peptides are fairly resistant to hydrolysis, and the extent and the velocity by which a 
dietary protein is broken down to its constituents is dependent on its composition (amino acid 
sequence) and on post-translational modifications such as glycosylation, which makes peptides more 
resistant to hydrolysis of proteases and peptidases (Daniel, 2004). 
The action of dipeptidyl peptidase IV (DPP-IV) and dipeptidyl carboxypeptidase I, as rate-limiting 
enzymes in the GIT, determines the digestive breakdown of the peptides (Daniel, 2004). 
Particularly, DPP-IV is a multifunctional type II transmembrane glycoprotein, expressed 
constitutively on epithelial cells of liver, intestine, kidney and in a soluble form as sCD26/DPPIV in 
the circulation. DPP-IV belongs to the prolyl oligopeptidase family, that preferentially remove N-
terminal dipeptides from substrates and thereby either inactivates peptides and/or generates new 
bioactive compounds (Röhrborn et al., 2015). DPP-IV takes part in a number of biological processes 
as both a regulatory protease and a binding protein. The enzyme is involved in glucose homeostasis 
achieved by its catalytic activity against the incretin hormones GLP-1 and GIP, beyond that cleaves 
a number of molecules such as neuropeptides, chemokines and regulatory peptides (Lacroix & Li-
chan, 2016). DPP-IV activity at intestinal mucosa level influences the amount and type of peptides 
passing into the bloodstream in intact form. Increased bioaccessibility and intestinal permeability, 
due to defective DPP-IV, can result in higher concentrations of bioactive peptides into the 
bloodstream. 
Current research in nutrition field aims to gain insights in the physiological role of dietary 
constituents, among them proteins are well known for their nutritional and biological value. Different 
types of protein such as egg albumen, milk protein, soy protein, pea protein, and wheat gluten have 
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also been investigated for their potential effects on health and satiety. Proteins and peptides make up 
one of the main groups of food bioactive compounds, and the investigation of their nutritional value 
is enclosed in a new emerging field defined nutritional proteomics or nutriproteomics (Sauer & Luge, 
2015). Recently, research in food science and nutrition changed the way food is considered. In fact, 
food is not just considerate as source of energy for the body, but it provides components with specific 
functions and nutritional properties, including potential benefits as well as possible adverse effects 
on health. 
Dairy products and milk are potential sources of bioactive peptides with extra-nutritional 
physiological functions, influencing many regulatory systems as glucose and lipid metabolism, blood 
pressure, immune function, food intake and body weight (Sauer & Luge, 2015). 
Furthermore, plant proteins represent valuable alternatives to animal proteins and are also cheaper 
and more sustainable. Still minor but nevertheless significant group of consumers, including 
vegetarian or vegan people, contributes to a trend of consuming plant protein sources (Capriotti et al., 
2016). 
Proteins influence appetite and food intake through the intestinal release of anorexigenic peptides 
such as PYY, GLP-1 and CCK. It is well known that taste may influence both appetite and food 
choice due to a strict interconnection between gustatory, metabolic and reward system (Steinert et al., 
2016). Nutrient sensing in the mouth and in the gastro-intestinal tract is mediated by the same types 
of receptors (GPCRs) that trigger amino acid-sensing.  
Some metabolites and amino acids contribute to the perception of postprandial satiety. This is at the 
basis of the aminostatic hypothesis (Veldorst et al., 2008). Accordingly, protein leverage hypothesis 
suggests that individual protein intake is regulated by individual protein target, emphasizing how 
‘protein target’ can drive energy intake (Martens & Westerterp-Plantenga, 2014). The ingestion of 
proteins or amino acids increases serum amino acid concentration that elicits appetite reduction; 
inversely, a fall of the amino acid serum concentration enhances appetite. This happens because 
amino acids work as satiety signal (Veldorst et al., 2008). Taste buds in the oral cavity initiate 
gustatory signaling that influence food liking and choice. The amino acid-sensing in the mouth is 
mediated by GPCRs. The heterodimer T1R1/T1R3 is the umami taste receptor that binds the L-amino 
acids such as L-glutammate (eliciting the umami taste) (Zhang et al., 2008). Together with 
T1R1/T1R3, amino acids are also sensed by gastrointestinal EECs through other GPCRs such as 
CasR, MORs and GPRC6A (G protein-coupled receptor family C group 6 subtype A) (Table 1). The 
binding between a certain peptide or amino acid with the specific receptor activates a signaling 
pathway that culminates with a release of satiating peptides (GLP-1, CCK, PYY) as well as 
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neurotransmitters that directly reach the brain and fire the reward area (Spreckley & Murphy, 2015; 
Vancleef et al., 2015). 
Table 1.   Amino acid taste receptors  
Receptor Localization Binding Function 
CasR ECCs, pancreatic 
cells 
Aromatic amino 
acids 
L-Phe, L-Trp 
 
Release of CCK and 
gastrin 
GPRC6A L-cells Basic amino acids 
L-Lys, L-Arg 
 
Release of GLP-1, 
increase [Ca2+] 
MORs 
 
 
 
Brain, GI tract, 
neurons of portal 
vein walls 
Nutropioids: 
 Antagonist 
Agonist 
 
Reduce food intake 
Increase food intake 
T1R1/T1R3 Mouth, stomach, 
small intestine 
L-glutammate Umami Taste 
receptors 
 
 
In particular, MORs are expressed both in the brain where they are involved in food reward system 
and in the small intestine where they control gut motility. MORs are present in the neurons of the 
portal vein walls and can sense blood peptides coming from dietary protein digestion. These peptides 
can act as MOR agonists or antagonists. The latter activate gut-brain mechanisms inducing the 
intestinal gluconeogenesis controlling food intake (De Vadder et al., 2013). The opioid signaling 
influences dietary behavior modulating individual ‘wanting’ of foods and ‘liking’. Interestingly 
“nutropioids” can result from the digestion of dietary proteins. Casomorphin from milk casein and 
exorphin from gluten are opioid ligands acting as opioid agonists (Pfluger et al., 2012). Interestingly, 
it was recently demonstrated in animals that high-protein diets increased TAS2R/Gαtran/Gαgust 
expression in the pyloric mucosa possibly due to the bitter taste of compounds forming by protein 
digestion or to some amino acids (De Giorgio et al., 2016). This feature highlighted the chemosensory 
adaptation of gastro-intestinal tract to the dietary nutrients raising the hypothesis that diets may 
modulate both metabolism and dietary behavior through the fine network of taste receptors.  
Consumption of dietary protein seems to decrease postprandial appetite and subsequent energy intake 
(EI) more than fat and carbohydrate. The type of protein ingested may also affect postprandial 
responses. A number of mechanisms have been proposed to explain this apparent satiety hierarchy of 
macronutrients, including higher thermogenic effect of dietary protein and post-absorptive small 
intestinal gluconeogenesis (which is associated with decreased EI in rats) (De Vadder et al., 2013). 
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Many oligopeptides coming from digestion of dietary proteins have opioid activity by acting as 
effectors of MORs (Pfluger et al., 2012). GIT, especially the small intestine, is the second body site, 
after brain, where MORs are most widely expressed and are involved in the control of gut motility 
and food intake (De Vadder et al., 2013).  
Soymorphins-5, -6, and -7 are opioid agonist peptides derived from β-conglycinin β-subunit of soy. 
They are able to suppress food intake and delay bowel transit time via gut μ-opioid receptor after oral 
administration as well as through the activation of serotonin (5-HT1A), dopamine D2, and GABAB 
receptors (Kaneko et al., 2010). 
Moreover, β-casomorphins (BCMs) are group of peptides with opioid properties arising by 
proteolytic digestion of β-casein (De Noni, 2008). Among the BCMs, BCM-7 is a typical peptide 
released during hydrolysis of the β-casein allelic variant A1, containing a histidine residue at position 
67 (Nguyen et al., 2015). BCM-7 exerts various physiological effects, i.e., secretion of mucus, 
increased activity of superoxide dismutase and catalase, increased levels of prolactin, analgesic role, 
slows down the passage of food through the digestive system (as do other opioids) providing longer 
time for lactose fermentation (ul Haq, 2014). 
In this scenario milk proteins are worthy of note because they are source of BAPs. 
Milk proteins are often suspected to be the cause of nonspecific, undiagnosed GI symptoms in adults. 
The manifestation of stomach symptoms in healthy subjects is affected by meal composition, which 
influence gastric emptying and thereby lactose load in the gut. Also, differences in individual 
sensitivity and gut microflora may affect the tolerability of milk (Turpenein et al., 2016). 
Opioid peptides are highly sensitive to hydrolysis by dipeptidyl peptidase IV (DPP-IV) thereby 
strongly limiting or preventing the transfer of these peptides in an intact form across the intestinal 
mucosa and the blood-brain barrier (De Noni et al., 2009). Increased intestinal permeability for 
digested food proteins and defective DPP-IV can result in biological active peptides circulating in the 
bloodstream, that can traverse the blood–brain barrier and reach the CNS (Cieślińska et al., 2015). 
 
1.4 Intestinal permeability and GI disorders 
 
Intestinal permeability can be defined as the facility with which intestinal epithelium allows 
molecules to pass through by non-mediated passive diffusion. This concept mainly refers to the 
passage of ions and inert molecules of low molecular weight. The intestinal transport of molecules 
from the intestinal lumen to the lamina propria can occur through two distinct mechanisms: 
paracellular diffusion through tight junctions (TJs) between adjacent intestinal epithelial cells (IECs) 
and transcellular transport involving endocytosis/exocytosis (transcytosis) mediated or not by 
membrane receptors (Ménard et al., 2010). There are a number of diseases that are known to increases 
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the mucosal permeation of macromolecules, such as celiac disease, Crohn’s disease, type 1 diabetes 
and patients with food allergies (Mishra & Makharia, 2012).  
A cross talk between gut and brain is consolidated. In addition, mounting evidence shows that gut 
microbiota can influence host appetite and eating behaviour by directly affecting nutrient sensing and 
appetite, for this reasons the microbiota-gut-brain axis has been coined (van de Wouw et al., 2017). 
The microbiota functions in tandem with the host’s defences and the immune system to protect against 
pathogen colonisation and invasion. It also performs an essential metabolic function, acting as a 
source of essential nutrients and vitamins and aiding in the extraction of energy and nutrients. 
(Carding et al., 2015). Alterations in the bowel flora and its activities are now believed to be 
contributing factors to many chronic and degenerative diseases. The intestinal dysbiosis hypothesis 
suggests a number of factors associated with modern Western living that have a detrimental impact 
on the microbiota of the GIT. In comparison to diets high in overall protein, diets especially high in 
animal protein have specific effects on intestinal microbiota (Myers, 2004). Intestinal permeability 
reflects just one function of the barrier that is intimately related to and interacts with luminal contents, 
including the microbiota. The mucosal immune response also influences barrier integrity although 
changes in barrier function have been described in several gastrointestinal disorders. It is important 
to note that the gut microbiota has a key regulatory role in both host metabolism and central appetite, 
which together can modify host eating behaviour in metabolic disorders and eating disorders. 
(Carding et al., 2015). 
Functional gastrointestinal disorders (FGIDs), are characterized by morphologic and physiological 
abnormalities that often occur in combination with motility disturbance, visceral hypersensitivity a 
well as altered mucosal and immune function, gut microbiota and CNS processes (Drossman, 2016). 
A complex interrelationship of predisposing genetic factors, influenced by life events as well as 
psychosocial factors lead to abnormalities in motility, visceral sensation, and brain – gut interactions, 
manifesting clinically as GI symptoms (Chey, 2013). 
The relationships between celiac disease (CD), Non-Celiac Gluten Sensitivity (NCGS), and irritable 
bowel syndrome (IBS) remain unclear. However, it has been a matter of debate whether barrier 
function contributes to the development of FGIDs or if it is merely a consequence (Barbara et al., 
2016).  
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1.1 Functional dyspepsia: definition, incidences and main symptoms 
 
Functional gastrointestinal disorders (FGIDs), are characterized by morphologic and physiological 
abnormalities that often occur in combination with motility disturbance, visceral hypersensitivity and 
altered mucosal and immune function, gut microbiota and central nervous system (CNS) processes.  
FGDIs are one of the leading causes for referral to emergency care units and represent 40% of 
diagnoses in gastroenterological settings (Drossman 2016).  Although only about 25% of 
symptomatic individuals seek medical support, the frequency of FGDIs drains substantial amounts of 
healthcare resources (Stanghellini 2017).  
According to the Rome IV committee, FGIDs can be classified into six groups: esophageal disorders, 
gastroduodenal disorders, bowel disorders, centrally mediated disorders of gastrointestinal pain, 
gallbladder and sphincter of Oddi disorders, and anorectal disorders (Oshima & Miwa 2018). 
Digestive function abnormalities and their symptoms, including functional dyspepsia (FD) and 
irritable bowel syndrome (IBS) are the most common FGIDs.   
FD refers to upper abdominal chronic symptoms arising from the gastroduodenal region mainly 
triggered by ingestion of food (Talley 2017). The prevalence of FD in the community ranges between 
5 and 11% (Vanheel et al.,2016).  
According to the Rome IV criteria, the diagnosis of FD is based on the presence of any combination 
of 4 symptoms such as postprandial fullness, early satiety, epigastric pain, and epigastric burning. 
Moreover, to get a positive diagnosis symptoms have to be severe enough to interfere with the usual 
activities with a frequency of at least 3 days per week over a previous 3 months-period with an onset 
of at least 6 months in advance (Drossman 2016). That definition identifies patients suffering from 3 
specific categories of disorders such as (1) postprandial distress syndrome (PDS), (2) epigastric pain 
syndrome (EPS), and (3) overlapping of PDS and EPS. PDS is characterized by meal-induced 
dyspeptic symptoms suggestive of a motility disturbance. EPS refers to epigastric pain or epigastric 
burning that do not necessarily occur after meal ingestion, can be even improved by meal, and is not 
associated with peptic ulcer or gastro-esophageal reflux disease. Overlapping of PDS and EPS is 
characterized by concomitance of meal induced dyspeptic symptoms and epigastric pain or burning 
(Stanghellini 2017). 
According to the Rome IV definition, the prevalence of FD is higher in USA (12%) than Canada (8%) 
and UK (8%) with a distribution of PDS and EPS similar in the combined population and across the 
three countries and genders, even if a higher prevalence of FD was found in women compared to men 
across all age groups (Aziz et al.,2018). In particular, most of the participants with FD fulfilled criteria 
for PDS (61%), followed by EPS (18%) and 21% overlapping variant with both syndromes. In 
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addition, subjects with PDS had overlap with irritable bowel syndrome (IBS 15%, vs. 42% with EPS) 
(Aziz et al., 2018), supporting the idea that the PDS subtype of FD is distinct from other FGIDs.  
A meta-analysis of 100 population-based studies comprising over 312,000 subjects showed that the 
pooled prevalence of uninvestigated dyspepsia was 21% (95% confidence interval, 18% to 24%) and 
that the risk of dyspepsia was increased in females and those with Helicobacter pylori infection, 
smokers, and nonsteroidal anti-inflammatory drug users (Talley 2017).  
The prevalence of FD is higher among women than men and this correlation could be due to sex-
specific biological differences in gastrointestinal function (for example, sex hormone-driven 
alterations in intestinal motility) or the processing of (visceral) pain in the CNS, but also to sex-
specific health care behaviour (Enck et al.,2017). 
 
1.2 Pathophysiology and biopsychosocial perspective of FGIDs  
 
The pathophysiology of FD is multifactorial and conclusive associations between symptoms and 
functional as well as psychological abnormalities are still a cause of debate among experts. It is well 
known that FD impacts on quality of life in a manner depending from symptom severity and comorbid 
depression. On the other hand, psychosocial disorders such as anxiety, depression, as well as physical 
and emotional abuse and difficulty in coping with life events are very frequent among FD patients 
(Stanghellini 2017). 
While a variety of peripheral candidate biomarkers related to FGIDs continue to be investigated, none 
appear to account for a large proportion of the symptom variance in this diversified set of syndromes. 
At the same time, a model for FGIDs that includes a prominent role for brain-gut interactions has 
been emerged over time. Brain-gut axis may explain the complex interconnections between 
gastrointestinal sensation, motility, immune function, and gut microbes with sensory, cognitive, and 
affective circuitry in the brain (Tillish 2018).  
In this framework, a biopsychosocial perspective is needed to shed light on how the complex 
interactions of environmental, psychological, and biological factors contribute to the development 
and maintenance of FGIDs as well as for an appropriate treatment of these comorbidities (Van 
Oudenhove 2016).  
The biopsychosocial model suggests that a complex interrelationship of predisposing genetic factors, 
influenced by life events as well as psychosocial factors lead to abnormalities in motility, visceral 
sensation, and brain – gut interactions, manifesting clinically as GI symptoms (Chey 2013). 
Psychological distress is a considerable risk factor for FGIDs development and, when present, can 
perpetuate or exacerbate symptoms. Comorbid anxiety and depression are independent predictors of 
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post-infectious IBS and FD but, at the same time, also occur as a consequence of bodily symptoms 
and related quality of life impairment. The absence of formal psychiatric comorbidity does not 
exclude a role of dysfunctional cognitive and affective processes (van Oudenhove 2016), likewise 
represent a big bias in the context of diagnosis of FGIDs.  In this frame it is essential clarify how each 
of these factors—the environment, the individual’s own psychological states and traits, and the 
individual’s (neuro)physiological make-up-interact to ultimately result in the generation of FGID 
symptoms (van Oudenhove 2016). 
 
1.3 Involvement and metabolic interactions of microbiome-gut-brain axis in 
FGIDs development 
A bidirectional communication takes place between gastrointestinal (GI) tract and central nervous 
system (CNS) through multiple pathways involving neural, endocrine, and immune cells. The gut–
brain axis (GBA) allows the CNS to regulate GI functions, including motility and secretion, and the 
GI tract to signal sensations such as hunger, pain or discomfort to the CNS. New emotional, cognitive 
and behavioural functions concerning the GBA have been discovered, including affective mood, 
memory formation and food intake respectively (Mazzoli & Pessione, 2016). FGIDs symptoms are 
not as easy to localize and are influenced more by overarching effects resulting from CNS–enteric 
nervous system (ENS) dysregulation of symptom control pathways (Drossman 2016). Brain imaging 
studies using functional magnetic resonance imaging (fMRI), positron-emission tomography (PET) 
or other emerging imaging technologies have identified alterations in several interconnected brain 
networks, including sensorimotor, emotional arousal and salience networks, in patients with FGIDs 
(Enck et al.,2017).   
Genetics and environmental factors as well as sociocultural influences may affect one’s psychosocial 
development in terms of personality traits, susceptibility to life stresses, psychological state, and 
cognitive and coping skills (Holtman et al., 2017). These factors influence the susceptibility to gut 
dysfunction: abnormal motility or sensitivity, altered mucosal immune dysfunction or inflammation, 
and the microbial environment, as well as the effect of food. This complex interactions and emotional 
distress may feed back to perpetuate and amplify symptoms (Sahan 2018). After exposure to stress, 
an increased basal activation of hypothalamic-pituitary-adrenal axis (HPA) and autonomic nervous 
system (ANS) associated with secretion of the corticotrophin releasing hormone (CRH) lead to 
physical and psychological symptoms, linked to GI system as well (Sahan 2018). The mechanisms 
underlying gut-brain communications involve neuro-immuno-endocrine mediators. This 
bidirectional communication network includes the CNS, both brain and spinal cord, the ANS, the 
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ENS and HPA axis. The HPA axis is considered the core stress efferent axis that coordinates the 
adaptive responses of the organism to stressors of any kind (Holtman et al.,2017). Environmental 
stress, as well as elevated systemic pro-inflammatory cytokines, activate this system that, through 
secretion of the corticotropin-releasing factor (CRF) from the hypothalamus, stimulates 
adrenocorticotropic hormone (ACTH) secretion from pituitary gland that, in turn, leads to cortisol 
release from the adrenal glands. Cortisol is a major stress hormone that affects many human organs, 
including the brain. Thus, both neural and hormonal mediators allow brain to influence the activities 
of intestinal functional effector cells, such as immune cells, epithelial cells, enteric neurons, smooth 
muscle cells and enterochromaffin cells (Carabotti et al., 2015). Both clinical and experimental 
evidence suggest that gut microbiota has an important impact on GBA, interacting not only locally 
with intestinal cells and ENS, but also directly with CNS through neuroendocrine and metabolic 
pathways involving serotonergic and GABAergic signalling systems (Barbara et al., 2016).  
FGIDs symptoms seem to be affected by microbiota in terms of microbial dysbiosis within the gut 
and its role in influencing anxiety and depressive-like behaviours (Foster & Neufeld 2013). Dysbiosis, 
that occurs in FGIDs, is highly associated with mood disorders as well. The break down 
communication of the GBA induce changes in intestinal motility and secretion, causes visceral 
hypersensitivity and leads to cellular alterations of the entero-endocrine and immune system. Gut 
microbiota may interplay with multiple of these different pathophysiological FGIDs targets and its 
role is supported by varying lines of evidence (Dupont 2014). 
The absence of microbial colonization is associated to an altered expression and turnover of 
neurotransmitters in both nervous systems (Clarke et al., 2013, Stilling et al., 2014) and also to 
alterations of gut sensory-motor functions, consisting in delayed gastric emptying and intestinal 
transit altered mucosal immune function, altered gut signalling (visceral hypersensitivity) and CNS 
dysregulation of the modulation of gut signalling and motor function (Carabotti et al.,2015). 
It was speculated that the high prevalence of psychiatric comorbidities in FGID patients reflects the 
fact that FGID may be a primary manifestation of brain dysfunction, or even primary somatization, 
with the brain driving the gut manifestations (Tanaka et al., 2011). Epidemiological data from 
prospective studies (Jones et al., 2012; Koloski et al., 2012; Koloski et al., 2016) suggest that in at 
least half of the cases, GI symptoms arise first and incident mood disorders occur later. Other studies 
emphasize the role of (intestinal) inflammation and cytokine response, and the gut microbiome in 
driving gut to brain alterations (Holtman 2017).  If these findings hold true, reversing GI dysfunction, 
could allow targeting and potentially curing not only the FGID but also concomitant mood disorders.  
Moreover, mounting evidence show that duodenal low-grade inflammation may be involved in the 
etiopathogenesis of FD inducing mucosal immune activation, duodenal barrier dysfunction, and 
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sensory-motor dysfunction. An altered duodenal gut microbiota, food antigens or infection may 
trigger duodenal micro-inflammation in a subset of FD patients (Jung & Talley 2018). 
The duodenum regulates acid secretion from the stomach and the nutrient absorption in the small 
intestine via local signalling pathways, and connects with the CNS, via neuronal and endocrine 
mediators. Duodenal eosinophils and in some cases mast cells may play a key role in immune 
activation in FD. Low-grade intestinal inflammation in patients with FD may provoke impairment in 
motor-sensory abnormalities along the gastrointestinal neural axis. Among FD patients, the risk of 
developing dyspeptic symptoms after a bout of gastroenteritis is 2.54 odds ratio (95% confidence, 
1.76-3.65) at more than 6 months after acute gastroenteritis (Futagami et al.,2015). Albeit causation 
is not established, the hypothesis that FD is a disorder of small intestinal inflammation in a major 
subset of patients is gaining acceptance, opening the possibility of novel and targeted treatment 
approaches. 
 
1.4 FGIDs and foods  
Food is associated with symptom onset or exacerbation in a significant proportion of FGID patients. 
Currently 80% of patients report that the symptoms are aggravated by ingestion of a meal (Page & Li 
2018) and particularly approximately two-thirds of patients report symptoms within 15–45 min of 
food ingestion (Pilichiewicz et al., 2009). Despite this, the role of food in the pathogenesis of the 
FGIDs has remained poorly understood. For this reason, diet has largely played an adjunctive rather 
than a primary role in the management of FGID patients, underestimating the role of food both in GI 
function and sensation as how food relates to GI symptoms in FGID patients as well (Chey 2013). 
Increasing evidence show that diet contributes to functional digestive symptoms (Feinle-Bisset, 2004; 
Gibson et al., 2015; Pilichiewicz et al., 2009), and dietary restrictions are frequent among patients 
affected by FGIDs, especially those suffering from IBS (Bohn et al.,2013; Gibson et al., 2015). The 
most common nutrients supposed of being attributable to FGIDs symptoms are dietary fibers, dietary 
fats, and carbohydrates (Feinle-Bisset 2013(b); Saito et al., 2005; Yang 2012, Moayyedi et al., 2014). 
Nowadays, most of people adopt unhealthy dietary patterns, characterized by high consumption of 
fat and sugary products, sodas, snacks, breakfast cereals and other ultra-processed foods (UPFs, high 
density of saturated fatty acids, sugar, sodium and low content of fibers). Several studies evaluate the 
possibility that UPFs could be related with increased risk of IBS or contribute to the induction and/or 
exacerbation of digestive symptoms (Buscail et al., 2017; Khayyatzadeh et al., 2016). At this regard, 
Schnabel and colleagues (2018) investigated the possible association between UPFs consumption and 
FGIDs (Schnabel et al., 2018). 
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A prospective observational cohort study including 3516 adult participants was carried out.  In the 
total population UPFs consumption accounted for 33.0% of total energy intake and the incidence of 
FGIDs was 10.5% for IBS, followed by functional constipation (5.4%), FD (3.9%), functional 
diarrhea (1.1%) respectively. Moreover, an increased proportion of UPFs in the diet was linked with 
a higher prevalence of IBS risk (aOR Q4 vs. Q1 [95% CI]: 1.25 [1.12–1.39], p < 0.0001), likewise 
an association between increased share of UPF in the diet and higher risk of FD when concomitant 
with IBS was observed (Schnabel et al., 2018). 
In dietary intervention studies, specific amounts of solid or liquid meals were served to determine the 
meal-related dyspeptic symptoms, gastric accommodation, or hormonal changes in FD patients (Lee 
et al., 2018). Although it is already known that FD patients tolerate only small amounts of food, 
evidence on the extent of nutritional intake of daily meals remains inconclusive (Feinle-Bisset 2013).  
Dietary recommendations in FD include eating smaller meals and avoiding high-fat meals which have 
been reported to aggravate clinical symptoms such as nausea and abdominal pain, more than 
isocaloric high-carbohydrate meals (Yamawaki et al.,2018). 
Recent studies investigating the role of dietary habit and nutritional intake in FD patients suggest that 
fat ingestion influences symptom development (Goktas et al., 2016, Khodarahmi et al., 2016). 
In particular, Goktas et al (2016) showed that FD subjects had symptoms mainly triggered by fried 
and fatty foods (27.1%), hot spices (26.4%), and carbonated drinks (21.8%) (Göktaş et al., 2016). 
In general, lipids in the duodenum can trigger gastric filling symptoms through a direct neuronal 
stimulation, higher lipid sensitivity of enteroendocrine cells or nerves, increased levels of systemic 
or local cholecystokinin (CCK, secreted by lipid-activated enteroendocrine cells, stimulates the 
release of digestive enzymes and bile and induces satiety) and/or increased sensitivity to CCK 
involving type A CCK-receptors (Enck et al.,2017). 
Evidence shows that in FD patients the intra-duodenal infused lipids (but not glucose) stimulate the 
stomach distension more than in healthy controls, thus suggesting a cross-sensitization between 
mechano-sensors and chemo-sensors (Barbera et al.,1995).  
Thus early satiety and intolerance of fatty foods in FD subjects could be related to gastrointestinal 
hypersensitivities to distension and/or small-intestinal fat (Feinle-Bisset 2013).  
Hypersensitivity to mechanical stimulation of the stomach is frequent in patients with FD, however, 
the underlying mechanisms for this hypersensitivity are unclear. There is some evidence that transient 
receptor potential (TRP) channels may be involved in the visceral hypersensitivity associated with 
FGIDs (Balemans et al., 2017). In particular, the TRP vanilloid receptor 1 (TRPV1) expressed on 
vagal and spinal sensory nerve endings in the gut wall and activated by low pH, high temperature, 
painful stimuli, exogenous irritants such as capsaicin (active component of hot chilli peppers; 
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Caterina et al., 1997) and endocannabinoids like anandamide seems the most involved (Zygmunt et 
al., 1999). Indeed, the consumption of spicy capsaicin containing food was positively associated with 
scores of stomach fullness in FD patients (Lee et al., 2018) and a hypersensitivity to capsaicin in 
patients with FD compared to healthy controls has been recently reported (Hammer et al., 2018). The 
chemical hypersensitivity to capsaicin characteristic of FD patients was used to develop a simple and 
minimally invasive oral test to identify subjects with FD (Hammer et al., 2018). 
 
Carbohydrates have been also associated to FGIDs as abdominal symptoms can be specifically 
induced by challenges with sugar (lactose or fructose), sorbitol, and oligosaccharides (fructans) alone 
or in combination and because exclusion diet-re-challenge tests in patients with FGIDs identified 
many cereal-based foods as those responsible to induce symptoms (Sheperd et al., 2013). 
Short-chain carbohydrates containing up to 10 monosaccharide units vary in their digestibility and 
subsequent absorption. Those that are poorly absorbed exert osmotic effects in the intestinal lumen, 
attract water, and are rapidly fermented by bacteria with consequent gas production (Sheperd et al., 
2013). As all dietary poorly absorbed short-chain carbohydrates have similar and additive effects in 
the intestine, a concept has been developed to regard them collectively as FODMAPs (fermentable 
oligosaccharides, disaccharides, monosaccharides and polyols) and to evaluate a dietary approach 
that restricts them all. Observational and comparative studies, and randomized-controlled trials 
support that FODMAPs trigger gastrointestinal symptoms in patients with functional bowel disorders, 
and that a diet low in FODMAPs offers considerable symptom relief in the majority of patients who 
use it (Yamawaki et al.,2018). Dairy or lactose intolerances and hypersensitivity to sour, acid-
secreting or irritant foods (for example, citrus, spices, coffee or alcohol) could also play a role in 
stimulating GI symptoms. In addition, protein-rich foods could have an effect as thy can contain 
hidden fat (not readily identified by patients) or cause specific immune responses (Enck et al.,2017). 
Studies using magnetic resonance imaging (MRI) confirm that when FODMAPs are administered to 
healthy volunteers, small bowel distension occurs due to increased small bowel water content. 
However, water retention in the intestine cause discomforts only in patients with FGIDs and altered 
sensory functions (Holtman et al.,2017). 
If FODMAPs are poorly absorbed and have been shown to induce symptoms in FGIDs, likewise 
gluten intolerance, even in the absence of coeliac disease, needs to be considered.  
In fact, IBS and FD patients, without evidence for celiac disease based on serological markers and 
histology, experience substantial improvement in symptoms upon withdrawal of gluten from their 
diet (Holtman 2017). The relationships between celiac disease (CD), “gluten-sensitivity,” and IBS 
remain unclear, with various studies reporting increased or expected rates of CD among IBS subjects 
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(Barbara et al.,2016). An overlap between IBS and Non-Celiac Gluten Sensitivity (NCGS) has been 
detected. NCGS is a syndrome characterized by intestinal and extra-intestinal symptoms related 
to the ingestion of gluten-containing food, in subjects that are not affected by either celiac disease 
or wheat allergy (Catassi et al.,2015). 
Epidemiology studies on IBS provide an indirect estimation of intestinal NCGS frequency. 
According to recent population-based surveys performed in Northern Europe, the prevalence of 
IBS in the general adult population was 16%–25% (Breckan et al., 2012; Krosgaard et al., 2013). 
In a selected series of adults with IBS, the frequency of NCGS, documented by a double-blind, 
placebo-controlled challenge, was 28% (Biesiekierski et al., 2011). Another study showed that 276 
out of 920 (30%) subjects with IBS-like symptoms, according to the Rome II criteria, suffered 
from wheat sensitivity or multiple food hypersensitivity, including wheat sensitivity (Carroccio et 
al., 2012). Should a consistent proportion of IBS patients be affected with NCGS, the prevalence 
of NCGS in the general population could well be higher than CD (1%) (Catassi et al., 2015). 
A recent systematic review of Duncanson et al., (2018) consolidated the already known relationship 
between dietary fats and FD. The apparently disparate set of foods reported as inducing symptoms 
are each high in either fermentable carbohydrate (some soft drinks, fruit, fruit juice, watermelon, 
milk), wheat/gluten (grain/pasta/wheat products, takeout/processed foods) or natural food chemicals 
(fruit, fruit juice, red pepper, soft drink, tea). The findings in relation to lactose and fructose 
intolerance suggest that FODMAPs may induce symptoms via the small or large bowel. From this 
review conducted from January 1982 to February 2016 only 16 studies out of 6451 studies met the 
inclusion criteria and they dealt with investigation about the effect of nutrients, foods and food 
components in adults FD patients. Of note, of this 16 studies only 5 were case-control studies and 1 
randomized controlled trial (RCT) characterized by a crossover gluten or placebo challenge. 
In two years, despite the relevance of food triggering FGIDs-symptoms, there is still the lack of data 
in literature related to RCT. Previous findings highlighted that FD is, at least in part, a disorder related 
to food ingestion per se, in which symptoms can be induced by specific foods or food components 
and not simply a postprandial gastrointestinal motility disorder. This highlights the need for well-
designed clinical studies that involve randomising patients to a wheat/gluten-free diet as well as 
controlling for FODMAP/fat content, aiming to investigate specific dyspeptic symptom associations.  
Furthermore, several lines of evidence suggest the involvement of the intestinal microbiota in the 
pathogenesis of FGIDs in general and IBS in particular. Gastrointestinal infections are strong risk 
factors for the development of FD and IBS, enhancing the intestinal permeability (leaky gut), within 
lifestyle and diet that are crucial determinants of microbiota composition and function in humans 
(Barbara et al., 2016). The impact of diet on the microbiota can be direct, through changes in its 
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composition or total energy supply, or indirect, via the induction of changes in intestinal transit time 
or intraluminal pH. Interestingly, the impact of diet on the microbiota is also highly dependent on the 
intestinal location: the conversion of complex indigestible carbohydrates is the driving force for the 
microbiota in the colon, whereas the fast uptake and conversion of sugars deriving from digestible 
polysaccharides mainly impact the microbiota in the small intestine (Barbara et al., 2016). 
 
Conclusion 
FGIDs are prevalent and debilitating GI disorders. The heterogeneity of these illnesses hints at a 
complex multifactorial pathophysiology including a role for the endocrine, immune, and nerve 
systems that are finely regulated by the microbiome-gut-brain axis.  
However, the molecular and cellular mechanisms behind the symptomatology are not yet fully 
elucidated.  
Although FD has been traditionally considered as a motility or acid-related disorder, mounting 
evidence shows that a subtle duodenal inflammation (notably, duodenal eosinophilia in a subset of 
patients with PDS), increased duodenal mucosal permeability, a disturbed duodenal microbiota, 
impaired ENS reflexes and systemic alterations (for example, increased levels of circulating cytokines 
and small-intestinal T cells) may be majorly implicated, thus shifting the interest from the stomach 
to the upper small intestine.  
In this frame the role of foods, diets and dietary components on etiology of the disease and 
symptomatology occurrence need to be developed. Large nutrition surveys with a prospective design 
could provide information on dietary habits of FGID subjects and clarify whether dietary preferences 
reflect the subconscious exclusion of foods to which subjects are intolerant. Moreover, long-term 
randomized controlled intervention trials are needed to identify foods that can reduce or even enhance 
the discomforts. 
Finally, some evidence shows that functional and molecular alterations of factors involved in 
intestinal permeability might explain FGIDs pathophysiology and symptom generation. More 
researches focused on this area may provide innovative and non-invasive biomarkers valuable in both 
diagnosis and assessment of drug and/or dietary therapy response in FGIDs patients.  
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Abstract 
Celiac disease (CD) is an immune-mediated inflammatory enteropathy triggered by gluten in 
genetically susceptible individuals. Gastrointestinal (GI) hormone response related to appetite and 
glucose metabolism are still under-investigated in patients with CD. This study aimed at shedding 
light on the appetite sensations, glycaemia and hormone response induced by a complex meal in celiac 
subjects. 
Twenty-two female subjects with CD, 9 at the diagnosis (CDD) and 13 under a gluten free diet 
(CDGF), and 10 healthy subjects (HS) were enrolled in a single day intervention study. All subjects 
consumed a test meal, recorded their appetite sensations and blood was collected over three hours 
after meal consumption. 
A lower decrease of hunger in CDD compared to CDGF and HS after meal intake was recorded. No 
difference of fullness and satiety between the groups was observed. CDD had lower insulin and GIP 
than CDGF and HS. Both CDD and CDGF experienced a lower post-prandial response of glucose 
than HS. 
Data suggested that patients with coeliac disease show an impaired glucose absorption after more 
than 12 months of gluten-free diet. Postprandial GIP may play a significant role in appetite cues and 
insulin response to a complex meal. 
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1.Introduction 
The incidence of celiac disease (CD) has significantly increased over the recent decades (Lohi 2007). 
A spectrum of disorders often coexists in patients with CD (Lauret 2013). It has been suggested that 
gluten consumption, along with gut permeability and inflammation, are factors in the development of 
type 1 diabetes (Smyth 2008). 
Type 1 diabetes mellitus develops in 1.6% to 16.4% of patients with CD (Al-Bawardy 2017). The co-
occurrence of insulin-dependent diabetes mellitus and celiac disease is linked to similar genetic 
background associated with the HLA (Human Leukocyte Antigen) class II genes on chromosome 
6p21 (Smyth 2008; Cronin 1997). 
Furthermore, mounting evidence showed that gluten-free diet (GFD) increased the risk of overweight 
or obesity in patients with CD who were normal weight or overweight at the diagnosis. That fact was 
associated to the improved intestinal absorption induced by GFD and to unhealthy dietary behaviour 
of CD patients who preferred foods rich in lipids, sugars and proteins (Mariani et al., 1998; Dickey 
and Kearney, 2006; Valletta 2010) and decreased dietary fiber intake (Mariani et al., 1998; Dickey 
and Kearney, 2006; Ferrara 2009). It is well-known that eating habits and preference result from 
metabolic, hedonic and cognitive factors (Rossi 2017).  
The metabolic factors associated to GF food consumption in CD patients were under-investigated. 
Post-prandial physiological mechanisms influence when and how much people can eat at the next 
eating occasion through modulation of appetite sensations (Berthoud 2017).  
Glucose plays a metabolic role in the control of hunger, satiety and the regulation of body energy 
balance (Chaput & Tremblay, 2009). A decreased glucose utilization or decreased intracellular 
glucose concentrations rather than the absolute level of blood glucose, work as the stimulus for meal 
initiation. 
The glucose uptake acts on the short-term control of hunger and food intake, argued by glucostatic 
theory of appetite control (Mayer 1953). The latter suggests that reduced glucose utilization in critical 
brain regions leads to perception and expression of hunger. Experimental evidence, together with 
glucostatic theory, suggests that pre-prandial hypoglycaemia, a reduced availability of glucose for 
metabolism and a decreased level of body carbohydrate stores or liver glycogen are stimuli for 
increased food intake (Chaput & Tremblay 2009). Both insulin and incretins play a key role in glucose 
variations. Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-
1) are major incretins with considerable effects on glucoregulatory functions (Edholm 2010). Edholm 
et al., (2010) showed that GIP dose-dependently reduces, postprandial glucose increment mainly 
through an increased insulin release and no effect on the gastric emptying rate. On the other hand, 
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GLP-1 displays dual effects on postprandial glucose control: an initial slowing of gastric emptying, 
and a subsequent increase of insulin release (Edholm 2010).  
Previous literature focused on the dosage of ghrelin in patients with celiac disease (CD), in particular 
describing a higher level of this peptide in CD patients at diagnosis and a lower level on a gluten free 
diet (Jarocka-Cyrta 2010, Rocco 2008), probably due to the changes in the nutritional state (Lanzini 
et al., 2006) or to the reduction of a systemic inflammation after diagnosis (Malandrino et al 2008).    
Ghrelin is a 28 amino acids hormone-like peptide mainly secreted by oxyntic glands of the gastric 
fundus. It has a pivotal role on the regulation of food intake eliciting the appetite (Schwartz MW et 
al 2000) and accelerates gastric emptying (Levin et al 2005), acting both to peripheral and central 
level. Therefore, circulating ghrelin concentration is high in fasting state and decreases in the 
postprandial period (le Roux 2006).  Conversely, glucagon like peptide 1 (GLP-1) decreases food 
intake, increases satiety, inhibits the acid secretion in the stomach and decelerates the gastric 
emptying (Gutzwiller et al 1999). This peptide is secreted by L-cells of distal ileum as well as in the 
gut and its release is mainly stimulated by both fats and carbohydrates intake.  
In this frame, a gap of knowledge still exists in the literature on the GI peptide response to a meal in 
CD patients in association to appetite sensations. 
The aim of this study was to evaluate the post-prandial appetite sensations induced by a mixed meal 
in celiac subjects at diagnosis and on a GFD and to clarify the role of gastro-intestinal response. 
To this purpose a single day intervention study was conducted in celiac and healthy subjects who 
consumed a test meal, recorded their appetite sensations and were submitted to blood drawings over 
three hours after meal consumption. Blood samples were analyzed to monitor gastro-intestinal 
hormone response related to appetite and glucose metabolism.  
 
2.Material & methods 
2.1 Subjects 
Enrollment of CD patients was carried out at the CD outpatient clinic of the University of Salerno 
and the Federico II of Naples. Eligible subjects were adult women, (aged 18-40 years) with normal 
weight (BMI 18.5-25 kg/m2) and with celiac disease (CD), diagnosed according to the current 
Guidelines (Ludvigsson 2014). CD diagnosis was based on the presence of gastrointestinal 
symptoms, Marsh ≥ 2 histology and antigliadin antibodies up to the year 1999 and in the presence of 
Marsh 2 histology and with both anti-tissue transglutaminase (a-tTG) IgA > 7 U/ml and positive anti-
endomysial (EMA) antibodies from the year 2000. Subjects with a diagnosis of CD were eligible to 
participate into the study. CD patients were at diagnosis (CDD), if they had received the CD diagnosis 
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over a month before the enrollment and CD on a GFD (CDGF) if they were on a GFD from at least 
12 months. 
A control group of healthy women was also recruited among the patients’ friends and the hospital 
staff. The inclusion criteria were the same as for the celiac patients as regards age and BMI but the 
CD and food allergies/intolerance as well as all gastro-intestinal diseases were excluded.  
For both groups of subjects (CD and healthy) those with eating disorders evidenced by Three Factor 
Eating Questionnaire (Stunkard & Messik 1985) were excluded.  
 
2.2 Study design 
It was a one-day study based on a test meal. The day before the experimental session subjects were 
asked to have a dinner consisting of a standardized meal including meat, vegetable, bread, and fruit, 
within 9 p.m. Fasting subjects were invited to reach the laboratory at 8 am. After checking for the 
health condition and absence of menstruation, and after 10 minutes of resting, a cannula needle was 
put in the arm vein. After 5 minutes of resting, a first blood sample was collected (0 min, baseline). 
Then a test meal was offered and blood samples were collected 30 min, 60 min, 120 min and 180 min 
after food intake. 
At each time point before blood collection, individual appetite sensations (including hunger, fullness 
and satiety) by visual analogue scale (VAS) were also recorded. 
The nutritional composition of the meal is reported in Table 1. It included: 100 g of gluten free bread, 
50 g of ham, 30g of cheese (stracchino type), 10g of butter, a yogurt and one apple. 
 
Table 1. Nutritional composition of the meal test. 
Meal test 
Protein 
(g) 
Fat  
(g) 
SFA 
(g) 
MUFA 
(g) 
PUFA 
(g) 
CHO 
(g) 
Fiber 
(g) 
Energy 
(kcal) 
         
Gluten free bread 100g 3.2 2.5 0.4 0 0 45.3 6.3 229 
Ham 50g 13.4 1.6 0.5 0.1 0.1 0 0 68 
Cheese 30g 5.6 7.5 4.7 2.4 0.3 0 0 90 
Butter 10g 0.1 8.3 4.9 2.4 0.3 0.1 0 75.8 
Yogurt 125g 4.8 4.9 2.6 1.1 0.2 5.4 0 82.5 
Apple 150g 0.5 0.2 0 0 0 20.6 3 79.5 
         
Total 27.43 25.00 13.0645 5.993 0.7795 71.34 9.3 624.8 
 
 
 
 37 
 
2.3 Blood sample collection and preparation 
For each time point, two different vacutainer® tubes of 4 mL each were used to collect plasma 
samples. A protease inhibitor mix, consisting of dipeptidylpeptidase IV (DPP-IV) inhibitor 
(Millipore’s DPP-IV inhibitor; St Charles, MO, USA), protease inhibitor cocktail (Sigma, St. Louis, 
MO, USA) and 4-(2-Aminoethyl)-benzenesulfonyl fluoride hydrochloride (AEBSF, Pefabloc® SC, 
Roche-diagnostics), was immediately added only into the blood destined to the GI peptide. After 
sample preparation, tubes were centrifuged at 4000 g for 10 minutes and plasma samples were 
aliquoted and frozen at -80°C, within 30 min from collection.  
Plasma samples were analyzed for gastrointestinal (GI) peptides concentration. Luminex 
Technology (Bio-Plex; Bio-Rad, Nazareth, Belgium) was used to determine GI peptides. A magnetic 
bead panel kit provided by Milliplex® (Merck Millipore, Millipore S.p.A.) allowed the simultaneous 
determination of the following four hormones: ghrelin, glucagon-like peptide-1 (GLP-1), glucose-
dependent insulinotropic peptide (GIP), and insulin. The sensitivity levels of the assay (in pg/mL) 
were: ghrelin 2.0; GIP 0.6; GLP-1 7.0; insulin 58.0. The intra-assay variation (%CV) was 2% for 
ghrelin, 3% for GIP and insulin; 7% for GLP-1. The inter-assay variation (%CV) was 5% for GIP; 
6% for insulin; 8% for ghrelin; 10% for GLP-1. 
 
2.4 Statistical analysis  
The analysis of variance (ANOVA) was performed to evaluate the differences between groups at each 
time points for both biochemical analysis and appetite scores. Since no difference at baseline for 
appetite scores was found, the results were analyzed and expressed as the absolute changes from the 
baseline. The subjective appetite sensations, the glycaemia and the response of hormones were tested 
for the effect of time as factor by the ANOVA for repeated measures. The linear trapezoidal rule was 
used to calculate the total area under the curves (AUC) for the appetite sensations and biochemical 
markers. Results are expressed as means ± SEM and were considered statistically significant for p < 
0.05. Statistical analyses were performed using Statistical Package for Social Sciences (version 16.0; 
SPSS, Inc., Chicago, IL, USA). 
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3. Results 
3.1 Subjects 
Twenty-two CD patients (9 at diagnosis, CDD, and 13 on a GFD, CDGF) and 10 healthy subjects 
(HS) participated into the study. Their general characteristics are reported as mean±SD in Table 2. 
The three groups were homogenous for age (p=0.09) and BMI (p=0.3). In CDGF the time passed 
since the start of gluten free diet was more than 5 years in 6 subjects, 3 years in 4 subjects, 2 years in 
2 subjects and 1 year in 1 subject. 
 
Table 2. Characteristics of study participants.  CDD: CD patients at diagnosis; CDGF: CD on a 
GFD; HS: healthy subjects. Data was reported as mean ± standard deviation. 
 CDD CDGF HS p value 
Age (years) 29.4±2.3 30.6±3.6 31.6±4.0 0.1 
BMI (kg/m2) 21.93±20.1 22.17±1.9 22.0±1.9 0.3 
a-tTG (U/ml) 142.83±28.2 2.84±0.02 − <0.001 
 
 
3.2 Appetite 
No significant difference of hunger, fullness and satiety sensations at baseline between the groups 
was found. Figure 1 shows the variations from baseline of appetite ratings over time.  Data showed 
a lower decrease of hunger in CDD compared to CDGF and HS after food intake.  
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Figure 1: Post-prandial appetite. Variations from baseline and area under the curve (AUC) of 
hunger (A), fullness (B) and satiety (C) feelings recorded during the study. Different letters indicate 
significant differences between groups (ANOVA and post-hoc Tukey test, p<0.05). 
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3.3 Hormone responses 
 
Figure 2 shows the time-concentration curve, the variation from baseline and the AUC of circulating 
ghrelin, insulin, GIP, and GLP-1. 
 
Figure 2: Post-prandial gastro-intestinal hormone response. Concentration-time response, 
variation from baseline and AUC of plasma concentration of ghrelin (A), insulin (B), GIP (C), 
GLP-1 (D) over the study, into the three groups of subjects. Different letters indicate significant 
differences between groups (ANOVA and post-hoc Tukey test, p<0.05). 
 
 
Data showed that CDD tended to have lower reductions of ghrelin in the post-prandial phase than 
CDGF and HS. No significant different AUC of plasma ghrelin over the three hours post-lunch 
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between groups was observed. CDD showed a lower response of insulin than CDGF and HS. Celiac 
subjects (both CDD and CDGF) showed a lower concentration of plasma GLP-1 at baseline and over 
the post-prandial phase than HS.   
Significant difference AUC of both plasma incretins GIP and GLP-1 over the three hours post-lunch 
was observed respectively. 
 
3.4 Blood glucose 
 
Figure 3 shows blood glucose concentration-time curve over the study and the AUC of glucose in 
the three groups. Data showed that celiac subjects (both CDD and CDGF) experienced lower post-
prandial response of glucose than HS (p<0.05). 
 
 
 
 
Figure 3: Post-prandial blood glucose. A) Concentration-time response over three hours post-
meal consumption in subjects with CD at diagnosis (CDD) and on a GFD (CDGF) and in healthy 
subjects (HS); B) AUC of blood glucose over three hours post-meal in the three groups of subjects. 
Different letters on the bars indicate significant differences between groups (ANOVA and post-hoc 
Tukey test, p<0.05) 
 
 
4. Discussion  
To the best of our knowledge, this is the first study investigating the post-prandial effect of a mixed 
gluten-free meal on appetite sensations, blood glucose response and gastro-intestinal hormone 
response in patients with CD at the diagnosis (before starting a GFD), on a GFD (under a GFD since 
at least 12 months) and in healthy subjects. 
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An important finding of this study was that in the post-prandial phase CDD showed a sustained 
hunger sensation and a reduced response of plasma GIP and insulin compared to CDGF and HS. In 
CDD, the lower hunger reduction could be explained by the lower GIP response than in CDGF and 
HS, in association with the lower GLP-1 than HS. Indeed, GIP and GLP-1, delay gastric emptying at 
physiological concentration (Marathe 2013). Therefore, a lower response of GIP in CDD, in addition 
to the low GLP-1 (as in CDGF vs HS), could determine a faster gastric emptying and, in turn, a faster 
returning of hunger. This picture is in accordance with the similar ghrelin responses recorded in the 
three groups and the evidence by Rocco and co-workers (2008) that the delayed gastric emptying in 
CD patients was not associated with reduced ghrelin levels (Rocco et al., 2008).  
Another important finding was the lower post-prandial glycaemia of celiac subjects, both CDD and 
CDGF, than HS. That finding was in agreement with the known condition for celiac patients of a 
decreased glucose absorption as observed in an old study by measuring jejunal transmural potential 
differences (Read et al., 1976) and as more recently demonstrated by Laforenza and co-workers 
(2010). These authors reported in duodenal biopsies of active celiac patients a reduced expression of 
the main solute transporters such as the Na+/glucose co-transporter 1 (SGLT1), the H+/oligopeptide 
transporter 1 (PEPT1) and Na+/H+ exchanger 3 (NHE3) thus revealing a clear mechanism 
underpinning impaired glucose, oligopetide and sodium absorption in those patients. Moreover, they 
showed that tissue expression of the transporters was completely restored in celiac patients consuming 
a gluten-free diet for at least 12 months. Our data suggested that this was not the case for our subjects 
even if they were all under a gluten free diet for a time longer than 12 months. However, the different 
hormonal response found into the two groups let us hypothesize the occurrence of concomitant 
mechanisms underpinning post-prandial glycaemia. In CDD, additionally to a supposed impaired 
glucose absorption, the low glycaemia was coherently associated with low responses of the incretins 
GIP and GLP-1 as well as of insulin. Contrarily, CDGF showed post-prandial insulin and GIP curves 
that were similar to HS. It is well known that GIP can reduce postprandial blood glucose by 
prolonging insulin release or, alternatively, by improving glucose uptake directly in the liver or other 
peripheral tissues, as well as by inhibiting glucose output from the liver (Edholm et al., 2010). 
Therefore, supposing a similar absorption rate of glucose, hormonal data suggested that an increased 
sensitivity of insulin and GIP in CDD compared to CDGF and HS might occur; this might explain 
the similar glucose curve of CDD and CDGF irrespective from GIP and insulin responses. In other 
words, GIP and insulin were more effective in glucose uptake at cellular level in CDD than CDGF. 
Such a phenomenon may be a physiological adaptive response of the body to the condition of 
malabsorption typical of CDD and is coherent with mechanisms occurring after weight loss (Asmar 
et al., Nutrition & Diabetes, 2016).  
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Interestingly, celiac subjects (both CDD and CDGF) showed a lower blood GLP-1 concentration than 
HS at every time point as previously shown by Papastamataki and co-workers (2014) in fasting 
children with celiac disease. Since no difference for post-prandial blood glucose between CDD and 
CDGF was found, similar circulating level of GLP-1 in the two groups supported a main role of this 
peptide in glucose management as well as the hypothesis (above discussed) of a similar 
expression/activity of SGLT-1 in CDD and CDGF in our study (Oguma et al., 2015). 
 
5. Conclusions 
This study shows the evolution of appetite sensations, blood glucose and the gastro-intestinal peptide 
response in celiac disease patients compared to healthy subjects over three hours after the 
consumption of a gluten free meal. 
Main data showed that CDD experienced a sustained hunger sensation and a reduced response of 
plasma GIP and insulin compared to CDGF and HS and celiac patients (both CDD and CDGF) 
showed a lower post-prandial glycaemia and blood GLP-1 than HS.  
A longer study is needed to verify the possible metabolic adaptations and homeostatic mechanisms 
that which may occur in celiac compared to healthy subjects.  
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Abstract  
Objective: The aim of this study was to assess the satiating efficacy of milk proteins compared to 
carbohydrates in twenty women during post-exercise period. 
Methods: A milk protein-enriched beverage (MPB), and an isocaloric carbohydrate-enriched 
beverage (CB) containing respectively 9.3 g and 0.3 g of milk proteins per 100 mL beverage, were 
developed and tested in a satiety study with 20 free-living healthy and normal weight women. The 
participants drank 250 mL of the two beverages after an aerobic exercise session, filled daily food 
diaries and rated their appetite on visual analogue scale (VAS), in two days over three consecutive 
weeks. A psychometric evaluation of eating behaviour by three-factor eating questionnaire (TFEQ) 
was obtained. 
Results: No differences in appetite feelings and energy intakes between MPB and CB were found in 
the study population. However, 9 participants were significantly less hungry (-9% vs +15%, p 0.03) 
and ate later (208 min vs 127 min, p 0.03) and less (-10% vs +8% daily energy intake, p 0.01) when 
they had MPB than CB. These women had a slightly higher BMI and were more restrained than the 
others.  
Conclusions: Data showed that MPB compared to CB could modify daily eating habits by enhancing 
satiety in women with a stronger cognitive control of eating behaviour.   
 
Keywords: milk proteins; appetite control; energy intake; eating behaviour; functional food.  
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1. Introduction 
 
Milk is recognised among foods with high biological and nutritive value. Some evidence showed 
promising effects of dairy consumption on body weight and composition. A key role for such effects 
was mainly attributed to protein content (Abargouei, Janghorbani, Salehi-Marzijarani, & 
Esmaillzadeh, 2012; Chen, Pan, Malik, & Hu, 2012). 
Bovine milk proteins are about 32 g per litre and comprise caseins (~80%) and whey proteins (~20%) 
(Haug, Høstmark, & Harstad, 2007). They are both high quality proteins containing all the essential 
amino acids but they have a different digestion and absorption behaviour: caseins (slow proteins) 
empty the stomach later and elicit a more sustained but prolonged increase of postprandial blood 
amino acids concentration than whey (fast proteins) (Boirie et al., 1997). Both protein types can delay 
gastric emptying. Furthermore, caseins induce the secretion of anorexygenic hormones such as 
cholecystokinin (CCK) and glucagon-like peptide (GLP-1) over a long term period (for a review see 
Bendtsen, Lorenzen, Bendsen, Rasmussen, & Astrup, 2013). Conversely, whey proteins due to 
glycomacropeptide and α-lactoalbumin as well as tryptophan (produced by digestion), induce CCK 
and serotonin secretion in the short-term period (Schellekens et al., 2014). 
A full consensus among researchers on the satiating effect of dairy proteins as well as on possible 
active dose or best way of consumption (i.e. through foods or beverages), was not yet established. 
Some studies tested the satiety effect of dairy proteins as constituent of yogurts or beverages. In those 
studies, amount of proteins ranged from 5g to 51g and they were included in portions with different 
size and energy value. Satiety effect was compared with similar isocaloric foods providing lower 
amount of proteins (Bertenshaw et al., 2009; Burton-Freeman, 2008; Douglas et al., 2012; El Khoury 
et al., 2014; Ortinau, et al., 2012) or carbohydrates as total replacement of proteins (Chungchunlam 
et al., 2014). Overall results showed different effects on appetite sensations, energy intake and delay 
of subsequent meal independently from the protein content of the foods. Such discrepancies among 
studies were due to the different protocols adopted and to the absence of a proper control food 
overcoming the interferences of fats and carbohydrates (Bendtsen et al., 2013). Interestingly, a 
common outcome from the literature could be highlighted: women were more sensitive to proteins-
rich foods than men (Bertenshaw et al., 2009; Burton-Freeman, 2008; Chungchunlam et al., 2014; El 
Khoury et al., 2014).   
Milk whey fraction is also a rich source of essential amino acids mainly branched chain amino acids 
which have a pivotal role in muscle metabolism and protein synthesis (Børsheim et al., 2002). Whey 
amino acid and electrolyte composition makes milk a good alternative to traditional sport drinks (for 
a review see Roy, 2008). Bovine milk has a short term hydration potential higher than still water and 
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commercial oral rehydration solutions (Maughan et al., 2016) and is more efficient to enhance the 
replacement of lost fluid following exercise than carbohydrate–electrolyte drinks (Desbrow, Jansen, 
Barrett, Leveritt, & Irwin, 2014; Watson, P., Love, T., Maughan, R., and Shirreffs, 2008).   
Previous evidence in the literature about the positive satiety effects of milk proteins in women and 
the potentiality of milk as a valuable sport drink (as discussed above) supported this study. It aimed 
to elucidate the satiety efficacy of milk proteins, added at 9% in a beverage, in comparison to an 
isocaloric beverage containing carbohydrates. To this purpose, the two beverages were developed 
and a randomized cross-over study involving women practicing exercise regularly was carried out. 
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2. Materials and Methods 
 
2.1 Beverages 
Two types of milk-based beverage with a different protein/carbohydrate ratio were developed. Both 
beverages were prepared from water diluted UHT (Ultra High Temperature) skim milk. That was 
added with milk proteins (Nutrilac-Be-8123, purchased by Arla Foods Ingredients Broups P/S, Vibj, 
Denmark) and a low-calorie sweetener in the case of the milk protein enriched beverage (MPB) 
whereas carbohydrates (25% maltodextrin, Dry MD 01910, Cargill®,Minneapolis, United States; 
25% corn starch, PolarTex™ 06739, Cargill®, Minneapolis, United States; 50% sucrose) were added 
in the case of the carbohydrate enriched beverage (CB). Table 1 reports nutrition facts of MPB and 
CB.The amount of milk proteins added in MPB provided the highest amount of proteins was possible 
without affecting beverage consistency. Starch and sugars in CB were added to balance both the 
calories and the consistency provided by milk proteins in MPB. Sweetness in MPB was adjusted 
using steviol glycosides (PURECIRCLE SDN BHD, Negeri Sembilan, Malaysia). The formulation 
of the beverages was optimised in order to make them as much as possible similar for taste, flavour, 
texture and colour. 
The beverages were UHT treated and were provided in 250 mL PET (polyethylene terephthalate) 
bottles that were singularly codified with an alphanumeric code. Each volunteer received 3 bottles of 
the two beverages on the week before starting the protocol.  
 
2.2 Amino acid composition of beverages 
Macronutrient content of MPB and CB was assessed by official methods of analysis of the 
Association of Official Analytical Chemists  (Horwitz, W., Chichilo, P., & Reynolds, 1970). 
Amino acid composition of the beverages was determined by Liquid chromatography–high-
resolution mass spectrometry (LC/HRMS) as previously described (Troise, Fiore, Roviello, Monti, 
& Fogliano, 2015). Two ml of beverage were centrifuged at 16000 × g for 10 min and the supernatants 
were separated and diluted (1:10) with a H2O/CH3CN (50/50) 1% formic acid solution.  
 
2.3 Subjects 
Recruitment was performed at the Department of Agricultural Sciences of University of Naples 
“Federico II” among students and staff. Eligible subjects were women, with a BMI in the range 18-
24.5 kg/m2 and with a moderately active lifestyle, as indicated by a physical activity level ranging 
between 600 and 1500 metabolic equivalents (MET)-min/week (Jettè et al., 1990). Subjects were 
excluded from the study if they had a BMI≥24.6 kg/m2 or ≤17.9 kg/m2, if they did not have planned 
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and structured physical activity (low physical activity, <600 MET-min/week) or they had high levels 
of physical activity (>1500 MET-min/week), if they had irregular menstrual cycle and any chronic 
illness such as diabetes or hypertension, if they were taking any prescription medication, or any type 
of supplement, or any performance-enhancing or recreational drug, or if they were under a controlled 
dietary regimen, or they lost body weight (changes ≥ 2 kg) over the previous three months, or they 
were pregnant or lactating women, or they were participating in other clinical trials.  
The physical activity was assessed through the International Physical Activity Questionnaire (IPAQ) 
(Hagströmer, Oja, & Sjöström, 2006) and the overall physical activity (3 hours per week) was 
expressed as MET.  
All participants also completed the three-factor eating questionnaire (TFEQ) that measures 3 different 
aspects of eating behavior such as restraint, disinhibition and hunger (Stunkard & Messick, 1985). 
The study protocol was approved by the Ethic Committee of University of Naples and the eligible 
subjects were enrolled in the study after signing an informed written consent.  
 
2.4 Study design 
A cross-over randomized double blind study was performed for three consecutive weeks, including 
two fixed experimental days per week, with one day wash-out in between (Figure 1).  
 
Figure 1. Study design indicating the experimental days and the randomization of beverages as well 
as the instruments and the measured outcomes over the study period.  
 
For each participant along the three weeks the experimental days were always the same week days. 
Once enrolled subjects were randomized for the order of beverage consumption over the three weeks. 
All subjects tested each beverage on three experimental days. On each experimental day immediately 
after exercise subjects consumed the beverage set out by the randomization. Subjects habitually 
exercised between 5:00 pm and 7:00 pm and they were required not to change time, type, intensity 
and volume of exercise over the study. Each woman started the protocol over the week following her 
menstruation in order to normalize the inter-individual impact of menstrual cycle on appetite. The 
volunteers were asked to reach the laboratory over the week before the start to get the coded beverages 
and a personalized calendar of consumption of the beverages. To evaluate the compliance to the 
protocol, at the end of each week, volunteers came to the laboratory and gave back the bottles; the 
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leftovers in the bottles were weighed. Moreover, they filled the IPAQ in order to monitor the level of 
physical activity over the past week. 
Dietary intake, appetite feelings, thirst, and beverage liking were recorded by subjects during all the 
experimental days. Diets and time of each meal were recorded in 24h weighed food diaries which 
were used to calculate energy intakes (EI) and macronutrient composition of each meal as well as the 
time of eating. 
Appetite sensations (hunger, fullness, satiety and desire to eat) were rated on a 100 mm visual 
analogue scale (VAS), anchored on the left as ‘‘not at all’’ and on the right as ‘‘extremely’’ in five 
specific moments during the experimental days: immediately before breakfast, at midmorning (11:00 
a.m.), immediately after lunch, before exercise and after exercise and beverage consumption. At the 
latter time point subjects also rated on specific VAS questionnaires their thirst and their liking (for 
sweetness, acidity, fatty taste, consistency, pleasantness and overall palatability) of the beverage they 
just consumed. 
Thirst was evaluated by VAS questionnaires. The subjects responded to the question, “How thirsty 
do you feel right now?” by marking on a line 100 mm in length with intersecting lines anchored at 0 
mm for “not at all” and at 100 mm for “extremely thirsty” (Marks et al., 1988; Stachenfeld et al.,1996; 
Stachenfeld et al., 1997). 
 
2.5 Statistical analysis 
Power analysis indicated that seventeen participants were sufficient to detect a minimum difference 
of 837 kJ (200 kcal) in EI with a power of 80% and an α=0.05 (Vitaglione P, Lumaga RB, Montagnese 
C, Messia MC, Marconi E, 2010). Twenty subjects were enrolled taking into account possible 
dropouts. 
Subjective appetite ratings and the EI were evaluated for differences by two-way repeated measures 
analysis of variance (ANOVA). When appropriate, differences between means were tested using the 
Student's t-test. 
Statistical analysis of data was carried out using SPSS (version 21, SPSS Inc. Chicago, IL, USA). 
Statistical significance was set at a level of α=0.05 (5 %). 
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3. Results 
 
3.1 Beverages  
Table 1 shows the composition of both MPB and CB per 100 mL. The beverages were isocaloric and 
differed for the proteins/carbohydrates ratio that was 3.7 in MPB and 0.03 in CB.  
 
Table 1. Nutritional composition of the Milk Protein (MPB) and of the Carbohydrate (CB) – enriched 
beverage per 100 mL. Values are reported as means ± standard deviations. 
 
 Milk Protein Beverage 
(MPB) 
Carbohydrate Beverage 
(CB) 
Energy (kcal) 47.0 47.0 
 g %Energy g %Energy 
Fat 0.03±0.001 0.60 0.03 0.60 
Carbohydrates 2.50 ±0.01 21.3 11.0±0.4 93.6 
 starch -  5.60±0.3  
 sugars 2.50±0.01  5.40±0.1  
Protein 9.30±0.2 79.1 0.30±0.01 2.50 
         added milk proteins 9.00±0.2  -  
Sodium 0.06±0.01  0.06±0.01  
Calcium 0.06±0.02  0.01±0.01  
     
Table 2 shows the amino acid content of both beverages. MPB contained about 9.3 folds higher 
amount of total amino acids (2608.9 μg/mL vs 279.38 μg/mL, p=0.001). 
Beverage formulations were selected in a preliminary sensory test on the basis of individual overall 
liking; beverages getting similar preference scores on VAS-based questionnaires were used in the 
study (data not shown). 
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Table 2. Amino acid composition of the Milk Protein (MPB) and of the Carbohydrate (CB) – 
enriched beverage. Data was reported as mean (μg/ml) ± SEM. 
 
Amino acids 
MPB  
Mean ± SEM 
(μg/ml) 
CB  
Mean ± SEM 
(μg/ml) 
TRP 52.70 ± 0.24 5.54 ± 0.10 
ILE-LEU 63.30 ± 1.87 14.83 ± 0.24 
PHE 65.32 ± 1.35 8.63 ± 0.31 
TYR 95.11 ± 1.35 9.99 ± 0.04 
VAL 611.05 ± 34.04 51.86 ± 2.08 
ALA 455.15 ± 63.09 31.53 ± 1.83 
PRO 101.27 ± 4.53 13.69 ± 0.31 
GLN 140.08 ± 2.59 27.92 ± 0.74 
GLU 302.25 ± 2.46 27.72 ± 0.11 
ASN 30.54 ± 0.23 3.08± 0.16 
ARG 219.32 ± 4.33 14.19 ± 0.24 
LYS 127.08 ± 1.98 12.81 ± 0.18 
HIS 78.33 ± 1.51 5.59 ± 0.04 
MET 38.60 ± 0.35 2.58± 0.09 
SER 171.40 ± 8.27 29.76 ± 0.28 
THR 57.40 ± 1.77 19.67 ± 0.22 
TOTAL 2608.9 ± 16.19 279.38 ± 3.55 
 
3.2 Human trial 
Table 3 reports the characteristics of the 20 women who participated into the study.  
Participants always drank whole portions of the provided beverages after their habitual exercise 
sessions, which were always at the same time (between 5:00 p.m. and 7:00 p.m.) and had the same 
intensity over the study weeks. 
Table 3. General characteristics of participants  
 
Mean±SD Range 
Age (years) 24±7 19 - 42 
Body weight (kg) 57.9±6.2 46 - 67 
BMI (kg/m2) 21.4±1.9 18.6 - 24.4 
F1 (Restraint) 11.9±3.7 5 - 18 
F2 (Disinhibition) 6.2±3.1 2 - 13 
F3 (Hunger) 3.8±4.0 0 - 13 
MET (min/week) 1188±129.4 1080 - 1440 
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Table 4 shows mean energy intake and nutrient composition of meals consumed during the 
experimental days, over the time period before and after exercise as well as each beverage 
consumption. 
 
Table 4. Energy intake and nutrient composition of meals consumed before and after exercise and 
beverage consumption. Data are reported as means of the three experimental days per beverage ± 
SEM (n=20).  
 Milk Protein Beverage  
(MPB) 
Carbohydrate Beverage 
(CB) 
 Before* After# Total Before* After# Total 
  Mean ± SEM   Mean ± SEM  
Energy intake (kcal) 892.03±36.34 463.06±48.12 
 
1355.10±40.38 905.08±23.83 472.29±43.59 1377.37±45.8 
Protein (g) 
%kcal 
31.84±2.03 
14 
29.09±4.07 
25 
60.93±2.84 
18 
35.53±2.61 
16 
26.39±2.89 
22 
61.92±2.92 
18 
Lipids (g) 
%kcal 
32.48±1.52 
33 
21.14±2.38 
41 
53.62±1.90 
36 
33.84±1.76 
34 
21.54±2.57 
41 
55.38±2.05 
36 
Saturated Fat (g) 
 
10.79±0.39 6.01±1.18 16.79±0.49 10.20±0.48 6.17±1.13 16.37±0.56 
Monounsaturated 
Fat (g) 
13.20±0.82 10.19±1.10 23.39±1.02 13.25±0.93 10.71±1.27 23.97±1.12 
Polyunsaturated Fat 
(g)  
4.40±0.22 2.97±0.49 7.37±0.28 4.42±0.30 3.17±0.53 7.60±0.34 
Carbohydrate (g) 
%kcal 
117.95±3.58 
53 
37.98±6.18 
33 
155.93±3.23 
46 
115.96±4.10 
51 
42.35±7.27 
36 
158.31±3.82 
46 
Starch (g) 
%kcal 
57.13±2.96 
27 
25.09±4.43 
23 
82.22±2.80 
26 
88.09±3.25 
17 
28.23±5.45 
25 
88.09±3.25 
27 
Sugars (g) 
%kcal 
46.64±0.91 
22 
9.97±2.23 
9 
56.60±0.81 
17 
38.95±0.81 
18 
9.83±2.69 
9 
48.78±0.70 
15 
Dietary fiber (g) 8.30±0.42 3.81±0.84 12.11±0.41 8.94±0.54 3.53±0.70 12.47±0.49 
* included breakfast, mid-morning snack, lunch, mid-afternoon snack. 
# included dinner and after-dinner snacks. 
 
Data showed no significant difference between energy intake and nutrient composition of the meals 
between the days over the same time period (before and after beverage) and between beverages. 
 
Figure 2 shows mean scores of appetite (hunger, fullness, satiety and prospective food consumption) 
sensations and thirst recorded by participants (n=20) over the experimental days when they drank 
MPB or CB. 
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Figure 2: mean scores of appetite (hunger, fullness, satiety and prospective food consumption) 
sensations and thirst recorded by the participants (n=20) over the three experimental days when they 
drank MPB or CB. 
 
No significant difference for any of appetite sensations or thirst at any moment of the day before and 
after the consumption of each type of beverage was found. 
However, considering individual daily energy intake during the time period before the 
exercise/beverage separately from the energy intake after the exercise/beverage, data showed that one 
group of 9 participants out of 20 ate significantly less (-10% vs +8% daily energy intake, p=0.01) 
when they had MPB after exercise than CB. The same participants were also significantly less hungry 
(-9% vs +15%, p=0.03) and ate later (208 min vs 127 min, p=0.03) over the post-exercise period after 
MPB compared to CB; conversely, they did not show any difference for fullness, satiety and 
prospective food consumption. Those 9 participants were named Responders (R) whereas the other 
11 were the Non-Responders (NR) hereinafter.  
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By a post hoc power analysis we calculated that 9 participants in this study were enough to guarantee 
a power of 86.8% with an α-error of 0.05, and 2-sided testing. 
Figure 3 and Figure 4 show energy intake and hunger before and after both beverages in R and NR. 
No difference of total daily energy intake between R and NR when they drank MPB or CB was found.  
 
 
 
Figure 3: Energy intake (EI) of Responders (n=9) and Non-Responders (n=11) before and after post-
exercise consumption of MPB or CB (line over the bars indicate significant difference p<0.05 
between MPB and CB in Responders after exercise).   
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Figure 4: Hunger rating of Responders (n=9) and Non-Responders (n=11) before and after post-
exercise consumption of MPB or CB (line over the bars indicate significant difference p<0.05).  
 
Data showed that NR compensate the calorie intake over the time period following exercise and 
beverage consumption. The higher EI at the meals (mainly dinners) over the evenings after MPB than 
CB was attributable to lower energy intakes at the meals (mainly lunches) before exercise time on the 
experimental days when NR drank MPB compared to CB (346.3 kcal MPB vs 437.5 kcal CB, 
p=0.02). On the contrary, R subjects had similar energy intakes during the time period before the 
consumption of MPB and CB (558.2 kcal MPB vs 526.3 kcal CB, p=0.59), therefore their reduction 
of caloric intake during the period following the post-exercise consumption of MPB was not due to a 
compensation effect.  
 
3.3 Thirst 
No significant differences for thirst sensation of all subjects over the test day (before breakfast, 
midmorning, before lunch, before exercise, after exercise/beverage) with CB and MPB (0.89 ± 1.43, 
p=0.54) were found. However, within R group, thirst sensation post-exercise and after CB 
consumption significantly increased compared to the pre-exercise time (p<0.001) whereas when 
subjects drank MPB, no significant difference of thirst before and after exercise was found (p=0.53). 
This finding was likely to be due to a lower thirst of R subjects before exercise over the days they 
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had CB compared to MPB (p=0.01). No differences of thirst in NR group neither before or after 
beverage consumption were found. 
 
3.4 Beverage liking 
Data about beverage liking for sweetness, acidity, fatty taste, consistency, pleasantness and overall 
palatability showed no differences between MPB and CB when all the participants or the two groups 
separately (R and NR) were considered (p>0.05). Therefore, the hedonic value of beverages could 
not have influenced the results of hunger or energy intakes at dinner in both R and NR.  
 
3.5 Characteristics of Responders and Non-Responders 
Table 5 shows general characteristics of population categorized as R and NR. Data showed that the 
two subgroups of subjects differed only for their eating behaviour. In fact, R showed a higher mean 
dietary restraint factor than NR i.e. R used to cognitively control their food intake compared to NR. 
In particular, the 9 R subjects showed a restraint score between 12 and 18 whereas among 11 NR, 8 
subjects showed a restraint score in the range 5 - 11 while the remaining 3 subjects showed a score 
of 12, 15, and 16. 
 
Table 5. General characteristics of R and NR (* p<0.05 vs NR)  
 
FEATURES RESPONDERS NON-RESPONDERS 
Number  9 11 
Age (years) 28±9 21±2 
Body weight (kg) 59.1±6.3 57.1±6.3 
BMI (kg/m2) 22.0±2.0 21.0±1.9 
F1 (Restraint) 14.4*±2.4 10.2±3.6 
F2 (Disinhibition) 5.1±2.3 7.0±3.4 
F3 (Hunger) 2.7±3.5 4.7±4.5 
MET (min/week) 1233.8±154.2 1152.0±99.2 
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4. Discussion 
In this study, a new protein milk rich beverage was developed and tested for its effects on satiety in 
women post-exercise. Data showed that 9 out of the 20 participants felt significantly less hungry and 
ate less and later when they drunk MPB compared to CB after exercise. These subjects were called 
Responders and scored higher Restraint value in the Three-Factor Eating Questionnaire than the other 
participants (Non-Responders).  
Previous studies showed an energy compensation effect after consumption of milk-based drinks 
offered to the participants in different volumes (Rolls & Roe, 2002). In the present study, the two 
tested beverages were isocaloric, the volume of administration was fixed (250 mL) and only women 
at the same phase of menstrual cycle participated into the study. A further strength of the study was 
the repeated consumption of the beverages for three-times during a three-week period while in 
previous studies beverages were tested by a single-acute consumption (Burton-Freeman, 2008; Chung 
Chun Lam, Moughan, Awati, & Morton, 2009; Desbrow et al., 2014; Hall, Millward, Long, & 
Morgan, 2003; Hursel, van der Zee, & Westerterp-Plantenga, 2009; Nieuwenhuizen et al., 2009; 
Shirreffs, Watson, & Maughan, 2007; Veldhorst et al., 2009a; Veldhorst et al., 2009b). 
Previous literature let us to hypothesize that MPB could increase satiety because of the high content 
of milk proteins including both caseins and whey proteins. The satiating effect of caseins could be 
induced by the hormonal response triggered by the circulating amino acids derived from digestion 
(Martens & Westerterp-Plantenga, 2014; M. Veldhorst et al., 2008; Veldhorst et al., 2009b). On the 
other hand, whey proteins were found more effective on satiety when compared to carbohydrates 
(Bellissimo et al., 2008; Bertenshaw, Lluch, & Yeomans, 2008). That effect was associated to whey 
content of the amino acids (Chungchunlam, S. M., Henare, S. J., Ganesh, S., & Moughan, 2016), as 
well as to glycomacropeptide (Chung Chun Lam et al., 2009) and α-lactalbumin which are able to 
enhance serum tryptophan (Nieuwenhuizen et al., 2009; Orosco et al., 2004), the precursor of 
serotonin (Schellekens et al., 2014). Serotonin could act on brain reward centres and reduce food 
intake by modulating food wanting (Born, Martens, Lemmens, Goebel, & Westerterp-Plantenga, 
2013; Fromentin et al., 2012; Journel, Chaumontet, Darcel, Fromentin, & Tome, 2012). 
Data of this study suggested that the MPB consumption (providing 23 g milk proteins compared to 
the 0.8 g of CB) reduced individual energy intakes in R by modulating mechanisms underpinning 
both energy and reward homeostasis. Moreover, data showed that individual restraint status was a 
key factor in satiating effect induced by MPB vs CB. 
The psychometric characterization of participants showed that those subjects having a more restrained 
attitude, i.e. a stronger control of their eating behaviour, were more susceptible to the satiating effect 
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of milk proteins compared to carbohydrates. That may explain the discrepant findings between 
literature studies on the satiating effect of dairy proteins (Bertenshaw et al., 2008; de Graaf, Hulshof, 
Weststrate, & Jas, 1992; Douglas, Ortinau, Hoertel, & Leidy, 2013; Marmonier, Chapelot, & Louis-
Sylvestre, 2000) or between men and women into the same study (Burton-Freeman, 2008; Chung 
Chun Lam et al., 2009). Chung Chun Lam and co-workers (2009) found that the consumption of ~40 
g of whey proteins modified dietary behaviour in women participating into the study but not in men; 
the restraint score of those women was higher (double) than men. That women are more restrained 
than men is what is usually occurring among people. Pohle-Krauza et al. (2008) showed that a rigid 
restraint status modulated the satiety response to phenylalanine possibly through effects of 
reproductive hormones (Pohle-Krauza et al., 2008). In the present study, women during all the 
menstrual cycle (the study lasted for three weeks and started the week after the menstruation) were 
involved, whereas the differences in the restraint status were a clear cut factor determining the 
satiating effect of MPB vs CB. This hypothesis is also supported by a fMRI study demonstrating that 
individual cognitive restraint was associated with inhibition of brain responses to hedonic food stimuli 
(Hollmann et al., 2012). Independent evidence suggested that cognitive control played a pivotal role 
to counterbalance a lack of homeostatic mechanisms or to reinforce physiological reduction of food 
wanting induced by high protein intake through the reward system. This is a key concept to implement 
personalized nutrition strategies and consumer-centred design of new food. More restrained people 
usually have a higher BMI than less restrained people because they use to alternate periods of 
excessive food consumption with periods of restriction, during which they try to monitor and regulate 
food intake through self-imposed rules (Bublitz, Peracchio, & Block, 2010). A milk protein-enriched 
beverage is more effective for energy control in this type of subjects and it may be a useful functional 
food for their body weight management.  
Data of the present study also showed in responders subjects the ability of MPB to maintain post-
exercise thirst similar to that perceived before exercise compared to CB despite the supposed 
dehydration induced by exercise. This finding was in line with literature studies showing that milk or 
milk-based beverages were more effective for post-exercise rehydration than traditional sports drinks 
and plain water (Shirreffs et al., 2007; Watson, P., Love, T., Maughan, R., and Shirreffs, 2008) or in 
comparison with carbohydrate–electrolyte drinks (Desbrow et al., 2014). Moreover, James et al. 
(2012) demonstrated that by replacing 2.5% of a 6% carbohydrate drink with milk proteins (and 
maintaining constant the energy density and electrolyte content of the beverages) an increased fluid 
retention was obtained (James et al., 2012).  
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It is worth of notice that in this study the subjects did not have similar thirst before exercising on the 
experimental days with MPB and CB, thus the initial thirst might have exalted the effect of MPB on 
thirst. 
The main limitations of this study were the lack of measurements of individual hormonal and neural 
signals as well as of hydration status during the experiments. The data available allowed us to 
hypothesize the mechanisms underlying satiety effect and thirst according to previous literature 
without clarifying the physiological pathways. On the other hand, the study design here adopted and 
based on a free living condition optimized the reliability of the findings compared to the laboratory 
environment that would have been necessary for studying the physiological mechanisms 
underpinning satiety and thirst.  
 
5. Conclusions 
In conclusion, compared to a carbohydrate rich beverage the milk protein-enriched beverage here 
developed was able to influence hunger sensation and reduce energy intake at subsequent meal in 
women having a strong cognitive control of eating behaviour in order to regulate their food intake for 
body weight control. In few words, data suggested that a milk protein-rich product may be useful to 
control food intake in dietary restrained women. Future studies should evaluate the effect on appetite, 
energy intakes, body weight and/or body composition of a long-term consumption of MPB in 
overweight/obese subjects with different eating behaviour. 
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Abstract 
 
Many oligopeptides coming from digestion of dietary proteins show opioid activity by acting as 
effectors of μ-opioid receptors (MORs). MORs are widely expressed in the gastrointestinal tract 
(GIT), especially the small intestine. β-casomorphins and soymorphins are a group of peptides with 
opioid properties arising by proteolytic digestion of β-casein and β-conglycinin β-subunit of soy 
respectively.  
To act systemically the bioactive peptides (BAPs) should be absorbed from the GIT and then reach 
the bloodstream in an active form. Activity inside the GIT may include induction of mucus secretion, 
analgesic role, and delay of bowel transit time. 
A gap of knowledge still exists on the effects of peptides/amino acids coming from digestion of casein 
and soy protein hydrolysates on barrier permeability in a condition of inflamed intestine. In this study, 
casein (CH) and soy (SH) protein hydrolysates were subjected to an in vitro simulated gastrointestinal 
digestion (SGID). Digested samples were administered to differentiated intestinal epithelial cells 
(Caco-2) in a normal condition and in an inflamed condition that was obtained by TNF-α 
administration into the culture. Markers of monolayer integrity (TEER) and cells viability (MTT and 
SRB) were measured in cell culture. 
Results of the assays demonstrated that the administration of CH and SH did not have toxic effects 
on cells and determined a response that was compatible with a full functionality of the cells. 
In conclusion, this study demonstrated that both hydrolysates may be protective towards intestinal 
inflammation, possibly acting on tight-junctions.   
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1.Introduction 
Caco-2 cells derived from human colon adenocarcinoma are a well-established model to evaluate the 
intestinal permeability and physiological response to food-derived peptides (Vieira et al., 2017).  
Upon a 3 weeks cultivation, the Caco-2 cells undergo a spontaneous differentiation leading to the 
formation of a cell monolayer displaying several morphological and functional characteristics of a 
mature enterocyte like microvillus structure, carrier-mediated transport system for di/tri-peptides, 
amino acids and glucose, tight junctions at the apical side and expression of several kinds of brush-
border enzymes. Therefore, Caco-2 cells can mimic all functions of the intestine epithelium including 
nutrient absorption (Yang et al., 2016). 
Dietary peptides can be directly absorbed or digested in the duodenum by pancreatic peptidases to 
form smaller peptides and/or amino acids. Some peptides are able to modulate intestine functions 
including nutrient absorption (Capriotti et al., 2016) such as casein phosphopeptides from milk that 
enhance mineral absorption, and soybean peptides suppressing dietary cholesterol absorption. Other 
peptides namely opioid peptides (including beta-casomorphin-7 and soymorphin-5,-6,-7) can regulate 
intestinal motility and glutamine-containing peptides can even prevent and/or repair damage caused 
by oxidative stress and inflammatory reactions (De Noni 2009,. Kaneko et al., 2010, Shimuzu et al., 
2017)  
The human intestine allows the absorption of nutrients while also functioning as a barrier, which 
prevents antigens and pathogens entering the mucosal tissues and potentially causing disease. 
Increased intestinal permeability is implicated in autoimmune, inflammatory, and atopic diseases, 
which can manifest both locally (within the intestinal mucosa) and systemically. 
A chronic inflammatory condition of the intestine, as found in inflammatory bowel disease and celiac 
disease, is characterized by a leaky intestinal barrier (Suenaert et al., 2002). Physiological conditions 
like stress have also been shown to increase epithelial permeability. The intercellular junctional 
complex has a crucial role in the maintenance of barrier integrity that can be deranged by pro-
inflammatory cytokines, such as as tumour necrosis factor-α (TNF-α). It can increase epithelial tight 
junction (TJ) permeability and contribute to intestinal inflammation in Crohn's disease and other 
inflammatory conditions (Ye et al., 2006; Ulluwishewa et al., 2011). Soybean proteins have been 
considered as a functional food ingredient. Particularly, the peptides from β-conglycinin could be 
absorbed by Caco-2 cell monolayers and the permeates could exert antioxidant and cytoprotective 
effects (Amigo-Benavent et al., 2014).  
In recent years, studies have established the important roles of glutamine in regulating the functions 
of TJ proteins (Yang et al., 2017). In human Caco-2 cells, glutamine deprivation or inhibition of 
glutamine synthetase significantly decreased the trans-epithelial resistance and the expression of TJ 
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proteins, and improved intestinal immunity (Ren et al., 2014a, 2014b, 2014c; Yin et al., 2014). The 
intestinal permeability can be modulated by proteins and amino acids. For example, an arginine-
rich protein decreases whereas L-alanine increases para-cellular flow (Jochems et al., 2018). 
Deficiency in amino acids such as tryptophan, arginine, glutamine, and cysteine can reduce immune 
cells activation. These amino acids have been shown to play unique roles in maintaining the integrity, 
growth, and function of the intestine, and in normalizing inflammatory cytokines secretion (Kong et 
al., 2018) 
The trans-epithelial transport routes of peptides vary for different peptides. Three major mechanisms 
for peptide transport have been identified in the intestine: i) peptide transporter-1 (PepT1), mediating 
the transport for di- and tri-peptides, ii) paracellular passive transport, via intercellular junctions and 
iii) transcytosis (Daniel & Zietek, 2015). Dipeptidyl peptidase IV (DPP-IV), represents the rate-
limiting enzymes in the GIT for bioactive peptides absorption as it can finalize their hydrolysis thus 
(thus inactivating them) or even generate new ones (Daniel et al, 2004; Röhrborn et al., 2015). Several 
distinctive factors, such as the molecular size, hydrophobicity and charge, influence the permeability 
of peptides across the intestinal epithelium (Wang & Li 2018). 
Recent findings in Caco-2 cell lines demonstrated that amino acids and peptides may exert anti-
inflammatory activity and protect intestinal barrier functions, by blocking TNF-α-induced 
inflammatory responses through allosteric activation of calcium-sensing receptor (Zhang & Mine 
2018). 
In this framework a gap of knowledge still exists on the effects of peptides/amino acids coming from 
digestion of casein and soy protein hydrolysates on barrier permeability in a condition of inflamed 
intestine.  
In this study, casein (CH) and soy (SH) protein hydrolysates were subjected to in vitro simulated 
gastrointestinal digestion (SGID). Digested samples were administered to differentiated intestinal 
epithelial cells (Caco-2) in a normal condition and an inflamed condition that was mimicked by TNF-
α administration. Markers of cell monolayer integrity (TEER) and cells viability were measured in 
cell culture. 
 
2. Materials and methods 
 
2.1 Protein hydrolysates 
 
Casein (CH) and isolate soy protein (SH) hydrolysates were provided by a. Costantino & C. spa 
(Favria, Torino, Italy).  
Nutrition facts of both ingredients are shown in Table 1.  
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Table 1. Nutrition facts of casein (CH) and isolate soy protein (SH) hydrolysates. 
 
Composition g/100 g CH SH 
Proteins 85 83.7 
Carbohydrates 8.1 3.0 
Total fats 
         of which saturated 
ND 
ND 
4.3 
31.8% 
Fibers 0.7 1.1 
Sugars ND ND 
Salt 3.5 4.88 
Energy value (kcal/kJ) 374 kcal/1588 kJ 388 kcal/1642 kJ 
 
 
2.2 Protein hydrolysate characterization 
 
Amino acid profile of the protein hydrolysates was determined by Liquid chromatography–high-
resolution mass spectrometry (LC/HRMS) as previously described by Troise et al., (2015), whereas 
the profile of food-derived BAPs was determined by a newly developed LC-Orbitrap-high-resolution 
mass spectrometry (HRMS) method. 
Hydrophobic peptides-markers targeted for a simultaneous detection were β-casomorphin-7, arising 
from β-casein of bovine milk, and Soymorphin-5,-6,-7, coming from β-conglycinin β-subunit of soy.  
Both casein and soy protein hydrolysates were suspended in water, centrifuged at 4 °C, for 15 min at 
21100 g and 100 µL was spiked with a known amount of internal standard (BCM-7, 100 ng/ml final 
concentration, Bachem , Zurich, Switzerland). Food samples were diluted up to 1 ml and loaded onto 
Oasis HLB 30 mg cartridges (Waters, Wexford, Ireland) previously equilibrated with 1 ml of each 
acetonitrile and 0.1% formic acid in water. Cartridges were washed twice with 0.1 % formic acid and 
BCMs and hydrophobic bioactive peptides were eluted with 1 ml of 0.1% formic acid in acetonitrile. 
Collected samples were dried by using a Savant centrifugal evaporator (Thermo Fisher Scientific, 
Bremen, Germany). Finally, samples were dissolved in 100 µL of water and 5 µL was injected.  
Chromatographic separation of hydrophobic-BAPs was achieved by using an Accela 1250 U-HPLC 
(Thermo Fisher, Bremen Germany) equipped with a Luna Polar C18 column (50 x 1.0 mm, 1.6 µm, 
Phenomenex, Torrance, CA) and a guard column of the same phase, both at 40° C. Mobile phases 
consisted of 0.1% v/v formic acid (A) and 0.1% v/v formic acid in acetonitrile (B) with the following 
gradient (min/%B): (0/2), (0.50/2), (4.5/90), (5.5/90). The flow rate was 100 µl/min and the column 
temperature was 40°C. The U-HPLC system was directly interfaced to an Exactive Orbitrap HRMS 
(Thermo Fisher Scientific, Bremen, Germany) and analytes were detected through a heated 
electrospray interface (HESI-II) operating in the polarity switch mode and scanning the ions in the 
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m/z range of 60–1300. The resolving power was set to 75000 full widths at half maximum (FWHM, 
m/z 200) resulting in a scan time of 1 s. 
The recovery test was performed by spiking hydrolysates with a known amount of BCM-7 (final 
concentration 0.5, 50, 500 ng/ml), a fixed amount of internal standard and taking into account the 
overestimation due to BCMs already present in the milk casein hydrolysate samples. Recovery was 
calculated plotting the area of the current associated to each m/z of target analyte in the matrix towards 
the concentration of the standard in the calibration curve. 
The tolerance range for mass accuracy of BCMs (i.e. the experimental mass of each analyte had to 
fall within the maximum permitted tolerance) was fixed at 5 ppm (Michalski et al., 2012). Data were 
recorded and analysed using Xcalibur software version 2.2 (Thermo Fisher Scientific, Bremen 
Germany). 
 
2.3 Simulated gastrointestinal digestion 
In vitro gastrointestinal digestion was performed on 1 g of CH and SH respectively, according to 
Minekus et al., (2014). Each sample was digested in triplicates and a blank sample (including all 
digestion fluids without hydrolysate) was run in parallel.  
At intestinal phase, an aliquot from each sample was collected and centrifuged at 2500 g for 10 min 
at 4°C. Supernatants were collected, separated and diluted (1:10) with methanol, centrifuged at 21100 
g for 5 min at 4°C and dried with nitrogen flow.  
Samples were stored at -25°C until analysis. 
 
2.4 Cell culture 
The human colon adenocarcinoma cell line (Caco-2) obtained from American Type Culture 
Collection were cultured in Dulbecco’s modified eagle’s medium (DMEM) supplemented with 
Glutamax (Gibco, Life Technologies, Carlsbad, CA, USA), 10% heat-inactivated fetal bovine 
serum (FBS, Greiner Bio One, Wemmel, Belgium), 1% penicillin–streptomycin (Pen Strep, Gibco, 
Life Technologies) and 1% non-essential amino acids (NEAA, Gibco, Life Technologies) (growth 
medium). The cells were grown in 75 cm2 canted neck tissue culture flasks (Sarstedt Co., Essen, 
Belgium) and incubated at 37 °C in a humidified atmosphere of 10% CO2 in air (Memmert CO2 
incubator, Memmert GmbH & Co., Nurnberg, Germany). The medium was replaced three times per 
week and cells were subcultured at 80-90% confluence using trypsinisation. Briefly, the cells were 
washed with 4 mL PBS (Gibco, Life Technologies) and were detached from the bottom of the flask 
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with 2 mL of 0.25% trypsin-EDTA wash (Sigma-Aldrich, Steinheim, Germany) and subsequently 
incubated at 37 °C and 10% CO2 in air for 3–5 min.  
A volume of suspension, depending on the cell concentration and passage number, was seeded to new 
flasks, and the final volume was made up to 4 mL with the DMEM medium with Glutamax, 10% 
FBS, 1% NEAA, and 1% Pen Strep (subculturing procedure). 
 
2.5 Measurement of cytotoxicity 
Caco-2 cells were seeded in 96-well plates, allowed to differentiate for 14 days after confluence. 
Each digested sample was previously re-suspended in distilled water, filter sterilized (Millex-GP, 
0,22 µm, Merck) and diluted (1/25) in exposure medium (DMEM supplemented with 1% Pen Strep, 
1%NEAA). 
Digested and diluted CH and SH (1/25) as well as blank of digestion (all digestion fluids without 
ingredients, DigBlank) were administered to Caco-2 cells. 
To analyse the cytotoxic effects of digested samples on Caco-2 cells after 4 hours of treatment, the 
3- (4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide (MTT) assay was applied.  
Briefly, 200 μL of MTT (Sigma-Aldrich) dissolved in PBS (5 mg/mL) was added to cells and 
incubated for 2 h at 37°C to convert MTT to formazan. After 2 h, the medium was removed, formazan 
crystals were dissolved in DMSO, and absorbance was recorded at 570 nm with a Bio-Rad multiplate 
reader (Bio-Rad Laboratories, Hercules, CA, USA). Furthermore, the measurement of cellular protein 
content was evaluated using the SRB assay as described in De Vreese et al. (2016). MTT and SRB 
assays were performed with 5 biological replicates (5 wells per condition).  
Control wells (untreated cells, exposure medium only) were included in the plate design. 
The results for both assays were expressed as percentage compared to untreated cells (viability). 
The same conditions described above were used when the inflammatory-condition was mimicked. 
Briefly Caco-2 cells were seeded in 96-well plates, allowed to differentiate for 14 days 
after confluence. TNF-α (10 ng/mL) was prepared in exposure medium and administrated to cells 
(1h). After 1h, the cells were rinsed and rested in exposure medium (1h) and then treated with digested 
sample (4h). Cytotoxicity was evaluated with MTT and SRB assay. Control wells (untreated cells, 
exposure medium only) were included in the plate design. 
The results for both assays were expressed as percentage compared to untreated cells (viability).  
 
2.6 Transepithelial transport study 
Caco-2 cells were grown and trypsinized as described above, suspended in growth medium and 
seeded in 12-Transwell ® plates (0.4 μm pore diameter, 12 mm insert, Elscolab, Kruibeke, Belgium) 
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at a density of 106 cell/well, with 500 μL of growth medium in the apical side and 2 mL of growth 
medium in the basolateral side. Cells were allowed to grow and differentiate to confluent monolayers 
for 21 days post seeding. Medium was changed three times per week. Passage numbers of the cells 
used in this study were less than 50. 
Transepithelial electrical resistance (TEER) was measured using an automated tissue resistance 
measurement system (REMS, World Precision Instruments, Hertfordshire, UK), to ensure that the 
monolayers exhibit the properties of a tight biological barrier. Only monolayers with a TEER value 
higher than 400 Ω·cm2 were used for the experiments (Wu et al., 2017). 
The experimental design of transport assay is shown in Figure 1. 
Digested CH and SH and DigBlank were suspended, filter sterilized (Millex-GP, 0,22 µm, Merck) 
and diluted (1/25) in exposure medium and then administered at the apical side (500 μL) of Caco-2 
cells. Untreated cells (cells in culture medium, without digested samples) were used as control.  
In order to investigate the cellular responses under high-grade inflammation-induced conditions, 
Caco-2 cells were preincubated for 1 h with TNF-α (10 ng/mL exposure medium) at basolateral side. 
A healthy/control batch (without TNF-α) were included in the study design (Figure 1). 
Monolayer integrity was tested by TEER before treatments (day 1, growth medium), before digested 
treatment with/without TNF-α (day 2, exposure medium). Then the exposure medium was replaced 
by growth medium, and the monolayers were incubated (24h) in order to measure irreversible damage 
to the cell monolayer (day 3) (Figure 1).  
Transport experiments were performed with 4 biological replicates (4 wells per condition) whereas 
TEER of each well was measured with 3 technical replicates. 
 
 
 
Figure 1. Experimental design of transport assay in healthy/inflamed condition  
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2.7 Statistical analysis 
 
MTT and SRB analyses were performed with 5 biological replicates (5 wells per condition).  
TEER and transport experiments were performed with 4 biological replicates (4 wells per condition) 
and 3 technical replicates (3 times each well).  
Data are expressed as mean values ± standard deviation (SD), whereas error bars in all the figures of 
MTT and SRB indicate relative standard deviation (RSD).  
To determine differences between treatments, one-way ANOVA followed by a Tukey post hoc test 
(p < 0.05) was applied using SPSS software (version 21.0, SPSS, Inc. Chicago, IL, USA). 
Statistical significance was set at a level of α =0.05 (5%). 
 
3. Results 
 
3.1 Amino acid profile determination 
 
Amino acid (AA) profile of casein and soy protein hydrolysates after SGID were evaluated.  
Figure 2 shows the AA content of CH and SH at each step of digestion (both gastric and intestinal 
phase). Figure 2 A and B shows the overall amino acid profile of digested CH and SH respectively, 
whereas Figure 2 C and D include essential amino acid (EAA) of digested CH and SH respectively. 
AA content of each hydrolysate at each digestion step is shown as Mean (ng/ml) ±standard deviation 
(SD). 
Data show a trend of reduction at intestinal phase vs gastric phase of most of AA. Conversely, an 
increase of γ-amino butyric acid (GABA) at intestinal phase of CH was recorded (Figure 2 A), whilst 
lysine and arginine of SH increase at intestinal phase (Figure 2 B and C). 
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Figure 2. Amino acid (AA) profile of casein and soy protein hydrolysates after SGID. Data are shown 
as mean ±standard deviation (SD). Statistical differences considering gastric vs intestinal phase for 
each AA was reported as * (p<0.05). A: AA profile of digested CH; B: AA profile of digested SH; C 
and D: zoom on essential amino acid (EAA) of CH and SH respectively. 
 
3.2 Hydrophobic bioactive peptides detection 
 
Hydrophobic biomarker β-casomorphin-7 (BCM-7) and soymorphin-5,-6,-7 were identified, and their 
fate during SGID were characterized. 
Figure 3 showed the fate of BCM-7 at each step of digestion. Data are represented as mean (g/ml) 
±standard deviation (SD). 
Particularly, an increase of rate of BCM-7 was recorded from hydrolysate (CH) to gastric phase 
(84,6%) as well as at intestinal phase (up to 23,8% then gastric phase).  
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Figure 3. Fate of BCM-7 at each step of digestion. 
 
Data relative to soymorphin-5,-6,-7 are shown as the mean value of area ± SD (Figure 4). 
An overall reduction at each step of digestion of soy-biomarker was recorded when compared to 
hydrolysate initial content. Particularly, soymorphin-7 was completely hydrolysed at intestinal 
phase when compared to hydrolysate, whereas soymorphin-6 increased at gastric phase and then a 
reduction was observed at intestinal phase. 
 
Figure 4. Fate of soy-biomarker at each step of digestion. 
 
 
 
3.3 Cytotoxicity  
 
Results of MTT (Figure 5) and SRB (Figure 6) assays on differentiated Caco-2 cells over 4h of 
treatment with digested protein hydrolysates in healthy/inflamed condition are shown as percentage 
of Viability ± Relative standard deviation (RSD). 
Data of MTT and SRB assays show that the administration of CH and SH had not toxic effects on 
cells. 
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Figure 5 shows that the administration of Casein hydrolysate at dilution 1/25 (CH) and soy 
hydrolysate 1/25 (SH) positively influenced cells viability particularly in inflamed cell condition. 
Figure 6 shows, a significant decrease of protein content of the cells treated with CH (vs the untreated 
ones) in inflamed condition; data from MTT assay excluded that the observed reduction was due to 
cell death. 
Protein content of the healthy cells were significantly influenced by SH probably due to a more 
efficient uptake of peptides and amino acids coming from in vitro digestion (Figure 6). MTT data 
confirmed a very good cell viability over the experiments. 
Digested casein and soy protein hydrolysates positively influenced cells viability. It seemed that 
Caco-2 became metabolically more active when they were treated with digested hydrolysates in 
inflamed condition (Figure 5). 
This data suggest a possible protective role of both digested hydrolysates in an inflamed condition 
was mimicked. 
 
 
 
 
Figure 5. Results (Viability ±RSD) of MTT assay after 4h of incubation in healthy (black bars) and 
inflamed condition (grey bars). Abbreviations: digested casein protein hydrolysates (CH), digested 
soy protein hydrolysate (SH), blank of digestion (DigBlank) all administered at dilution of 1/25. 
Untreated cells (Untreated, only medium). 
Statistical differences compared to untreated cells in healthy conditions are denoted as # (p < 0.05) 
whereas statistical differences compared to untreated cells in inflamed conditions are denoted as * 
(p<0.05) 
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Figure 6. Results (Viability ±RSD) of SRB assay after 4h of incubation in healthy (black bars) and 
inflamed condition (grey bars). Abbreviations: digested casein protein hydrolysates (CH), digested 
soy protein hydrolysate (SH), blank of digestion (DigBlank) all administered at dilution of 1/25. 
Untreated cells (Untreated, only medium). 
Statistical differences compared to untreated cells in healthy conditions are denoted as # (p < 0.05) 
whereas statistical differences compared to untreated cells in inflamed conditions are denoted as * 
(p<0.05). 
 
3.4 TEER  
 
Table 2 shows TEER (Ω·cm2) values of Caco-2 cells treated with digested casein and soy protein 
hydrolysates (CH and SH respectively, dilution 1/25) and blank of digestion (DigBlank 1/25) during 
different experimental days, whereas TEER values of inflamed condition are reported in Table 3. 
Data are shown as Mean ± SD; numbers in brackets represent the TEER values relative to the initial 
TEER value, expressed as percentages. Different letters in the rows represent statistically significant 
differences (p < 0.05).  
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Table 2. TEER (Ω·cm2) evaluation of Caco-2 cells treated with digested casein and soy protein 
hydrolysate in healthy condition. Different letters in the rows represent statistically significant 
differences (p < 0.05).  
 
 Day 1 Day 2 Day 3 
Untreated cells 1952.3±31.1 
a
 
 
1998.4±35.0 
a
 
(102.4%) 
1976.1±30.3 
a
 
(101.2%) 
CH  1/25 1920.8±33.8
a
 
 
1929.4±37.8 
ab
 
(100.4%) 
1964.4±8.0 
b
 
(102.3%) 
SH  1/25 1961.3±8.11 
a
 
 
1995.1±18.7 
a
 
(101.7%) 
2017.3±12.6 
a
 
(102.9%) 
Dig Blank 1/25 1945.2±21.1 
a
 1964.2±15.5 
a
 
(100.6%) 
1928.9±16.5 
a
 
(99.5%) 
 
 
Table 3. TEER (Ω·cm2) evaluation of Caco-2 cells treated with digested soy and casein hydrolysate 
in inflamed condition. Different letters in the rows show statistically significant differences (p < 0.05).  
 
 
 
 
 
 
 
 
 
TEER data showed no irreversible damage at the normal and inflamed cell monolayer when treated 
with digested samples. Particularly, CH enhanced TEER (p<0.05) compared to the baseline values of 
normal cells (Table 2. day 1). A possible increase of TEER values between day 1 (preliminary TEER 
evaluation) and day 2 (effective day of treatment) is due to change of medium (Table 3). No 
significant change in TEER values between day 2 and 3 were reported, showing that the hydrolysate 
may play a role on tight junction integrity in high grade of inflammation state. 
 
 
 
 
 Day 1 Day 2 Day 3 
Untreated cells 1641.5±78.3 
a
 
 
1849.5±32.7 
b
 
(112.7%) 
1894.5±31.5 
b
 
(115.4%) 
CH  1/25 1749.1±45.8
 a
 
 
1924.9±59.0 
b
 
(110.0%) 
1943.0±56.9 
b
 
(111.1%) 
SH   1/25 1673.8±62.1 
a
 
 
1944.9±25.9 
b
 
(116.2%) 
1963.4±19.0 
b
 
(117.3%) 
Dig Blank 1/25 1690.7±54.5
a
 1934,9±47,6 
b
 
(114.4%) 
1938.6±45.6 
b
 
(114.7%) 
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4. Discussion 
 
Caco-2 cells derived from human colon adenocarcinoma are a well-established model to evaluate the 
intestinal permeability and physiological response to food-derived peptides (Vieira et al., 2017).  
Increased intestinal permeability is implicated in autoimmune, inflammatory, and atopic diseases, 
which can manifest both locally (within the intestinal mucosa) and systemically. 
A TNF-α-induced increase in intestinal epithelial TJ permeability was proposed to be an important 
pro-inflammatory mechanism contributing to intestinal inflammation in Crohn's disease and other 
inflammatory conditions (Ye et al., 2006).  
Several food bioactive components were reported to exert anti-inflammatory activity. Recently, milk-
derived hydrolysates have been reported to exhibit anti-inflammatory activity in endothelial cells 
(Marcone, et al., 2015), whereas casein-derived peptides and amino acids improved Caco-2 TEER, 
primarily through the increased expression of the TJ proteins (Beutheu et al.,2013, Li et al., 2004; 
Yasumatsu &. Tanabe 2010).  
Several studies have reported that a variety of amino acids or oligopeptides, tryptophan, γ-glutamyl 
peptides, polylysin and protamine, were able to block TNF- α-induced inflammatory responses in 
both Caco-2 cell lines through allosteric activation of CaSR (Zhang & Mine 2018). 
Furthermore, the role of glutamine in regulating the functions of TJ proteins is well established, 
whereas dietary L-arginine supplementation improved intestinal recovery following mucosal injury 
in rats.  
Barrier enhancing effects by protein hydrolysates were shown by Visser et al., (2010 and 2012), who 
fed diabetes prone rats with casein hydrolysates for 150 days and measured the barrier function. This 
study showed that casein hydrolysate intake decreased the epithelial permeability compared to a diet 
with sole amino acids. This benefit was evidenced by a normalization of the TJ mRNA expression, 
and an up-regulation of the regulatory and anti-inflammatory cytokine Interleukin (IL)-10. Multiple 
bioactive tri- and tetrapeptides derived from soy and whey have been found to induce anti-
inflammatory effects after being taken up into the cell (Dalmasso et al., 2008; Kovacs-Nolan et al., 
2012; Oyama et al., 2003) by PepT1, that is expressed in the small intestine, but during inflammation, 
is also up-regulated in the colon (Adibi et al., 2003). Treatment with the soy peptides KVP (lysine, 
valine, proline) and VPY (valine, proline, tyrosine) and the whey peptide IPAV (isoleucine, proline, 
alanine, valine) all showed a decrease in the production of the pro-inflammatory cytokines IL-6, IL-
8, and TNF-α in Caco-2 cells. This effect disappeared when PepT1-activity was inhibited, indicating 
that transport via PepT1 is necessary for the anti-inflammatory effects. Peptides derived from many 
different food protein sources are known to bind opioid receptors (Stefanucci et al., 2018). Although 
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endogenous opioid peptides have a main function as neurotransmitters, they are also known to 
modulate innate and acquired immune responses (Liang et al., 2016). These effects have also been 
described in immune cells after hydrolysate administration. Therefore, it cannot be excluded that 
protein hydrolysates also modulate the immune system via opioid receptors. 
Overall, this experimental evidence supports the potential of casein and soy protein hydrolysates to 
positively influence the barrier permeability in inflamed condition of the gastrointestinal tract.  
 
5. Conclusion 
 
This study showed that casein and soy protein hydrolysates may restore inflammation-induced 
intestinal barrier dysfunction of Caco-2 cells. In the presence of inflammatory stimulus, the protein 
hydrolysates ameliorate and preserve the intestinal barrier possibly acting at TJ level.   
Simulated gastrointestinal digestion of the hydrolysates increase the bioavailability of BAPs and 
amino acids, enhancing the chance of these compounds to be absorbed and to exert a biological effect. 
Taken together, these results suggest that BAPs and amino acids can regulate the intestinal epithelial 
barrier structure and functions, restoring the properties (and functions) of intestinal epithelial cells. 
Future studies should evaluate this activity in vivo. 
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Abstract 
Dietary proteins may contain some bioactive peptides (BAPs) encrypted within their primary 
structures. BAPs may be delivered in the food during processing and/or in the gastro-intestinal tract 
during food digestion and can exert some biological effects beyond nutrition such as antimicrobial, 
anti-thrombotic, antihypertensive, opioid and immunomodulatory effects. BAPs modulating blood 
glucose response are promising ingredients for functional foods development. They work through 
inhibition of the enzyme dipeptidyl peptidase IV (DPP-IV) that modulate glucose homeostasis by 
cleaving glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. 
The aim of this study was to evaluate the potential activity of casein (CH) and soy (SH) protein 
hydrolysates as well as of CH and SH enriched biscuits (CHB and SHB) on post-prandial glucose 
response in vitro. 
Control biscuits (ConB) without protein hydrolysates and two types of CH and SH-enriched biscuits 
providing 4.5% (CHB1 and SHB1) and 13% (CHB2 and SHB2) of each hydrolysate were developed. 
CH, SH, CHB1, CHB2, SHB1 and SHB2 were subjected to in vitro simulated gastrointestinal 
digestion and the ability of the digested samples to inhibit DPP-IV activity was assessed. In vitro 
glycaemic index (GI) of the biscuits was also measured.  
Data showed that CH and SH behaved as mixed and competitive inhibitor of DPP-IV with an IC50 
of 2.59 mg/ml and 3.56 mg/ml (p<0.05), respectively, when tested alone. No significant difference 
between digested biscuits for the inhibition of DPP-IV activity was observed. The GI of the biscuits 
was in the order ConB> CHB1>SHB1>CHB2>SHB2. This study suggested that CH and SH maybe 
functional ingredients for glycaemia control through inhibition of DPP-IV activity. A food matrix 
effect could hide the bioactivity of CH and SH at the doses used in the biscuits during in vitro 
enzymatic digestion.    
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1.Introduction 
A large body of research focuses on bioactive food ingredients and compounds i.e. those able to 
provide health benefits in consumers and specifically in people at risk to develop chronic diseases. 
Among promising bioactive compounds, particular interest was recently gained by some food-derived 
peptides for the ability to regulate glycaemia, possibly through inhibition of the enzyme Dipeptidyl 
Peptidase IV (DPP-IV). DPP-IV is a multifunctional type II transmembrane glycoprotein, expressed 
constitutively on epithelial cells of liver, intestine, kidney and in a soluble form as sCD26/DPPIV in 
the circulation. DPP-IV belongs to the prolyl oligopeptidase family, that preferentially remove N-
terminal dipeptides from substrates and thereby either inactivates peptides and/or generates new 
bioactive compounds (Röhrborn et al., 2015). DPP-IV takes part in a number of biological processes 
as both a regulatory protease and a binding protein. The enzyme is involved in glucose homeostasis 
achieved by its catalytic activity against the incretin hormones glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP), beyond that cleaves a number of molecules such 
as neuropeptides, chemokines and regulatory peptides (Lacroix & Li-chan 2016). Of the twelve 
classes of glucose-lowering drugs currently available for the management of diabetes, inhibitors of 
DPP-IV are among the newest agents to have been introduced to the type 2 diabetes pharmacopeia, 
preventing the degradation of gut-derived hormones that play a pivotal role in glycaemic homeostasis 
(Filippatos et al., 2014).  
Bioactive peptides (BAPs) are short amino acid sequences that coming from processing and/or 
digestion of dietary protein, which exert a measurable biological effect on body functions and health 
(Mo and Roos, 2008). Several food peptides are known to possess regulatory functions that can lead 
health benefits as demonstrated mostly through in vitro, cell culture and animal studies. Some dietary 
peptides show antihypertensive, antioxidant, anti-inflammatory, hypolipidemic, anticancer, 
antidiabetic and antimicrobial properties (Udenigwe and Fogliano, 2017).  
BAPs and amino acids trigger GLP-1 secretion (Chang et al., 2013; Haberer et al.,2011; Steinert et 
al., 2014), involved into meal-related glycaemic control by stimulating insulin secretion (i.e., acting 
as an incretin), inhibiting glucagon secretion, slowing gastric emptying, and reducing hepatic glucose 
metabolism (Steinert et al., 2016) 
Diet is well recognized to play an important role in the prevention and management of diabetes and 
particularly, protein hydrolysates are recognized as a potent source of BAPs. In fact, consuming 
protein hydrolysates containing these peptides might be helpful in the management of many 
western diseases like inflammatory bowel diseases, allergies, and diabetes (Kiewiet et al., 2018). 
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Mounting evidence reported putative associations between the consumption of certain foods, or their 
constituents, and the incidence of diabetes (Lacroix & Li-Chan, 2014a). Moreover, compelling 
findings from in vitro as well as animal and clinical studies have shown that some dietary factors, 
such as peptides and phenolic compounds, can help regulate blood glucose levels (Lacroix & Li- 
Chan, 2014a). Recent research suggested that one of the plausible mechanisms of action underlying 
the anti-diabetic effect of various food commodities could reside in the ability to inhibit the DPP-IV 
enzyme (Lacroix & Li-Chan, 2012). Dietary factors that are natural sources of DPP-IV inhibitors 
could potentially complement pharmacotherapy in the regulation of blood glucose levels. A variety 
of common food, including milk, egg, fish, corn, as well as amaranth, quinoa and hemp, have been 
explored to produce protein hydrolysates and peptides with DPP-IV-inhibiting properties 
(Nongonierma et al., 2015; Nongonierma et al.,2017). To date, proteins from cow's milk have been 
the most extensively investigated sources of DPP-IV inhibitors in vitro, in the form of hydrolysates 
of dairy ingredients, casein and whey fractions of milk (Lacroix & Li-Chan 2012; Nongonierma et 
al., 2017). Additionally, protein digests produced by in vitro simulated gastrointestinal digestion have 
also been reported to be able to inhibit DPP-IV activity (Lacroix & Li-Chan 2016), therefore 
suggesting that DPP-IV inhibitory peptides might be generated in vivo during the digestion process.  
The relevance of studying whole foods instead of single nutrients is becoming clear as potential 
nutrient–nutrient interactions may affect the metabolic response to the whole food compared to its 
isolated nutrients.  
In this frame, the aim of this study was to evaluate the potential activity of casein (CH) and soy (SH) 
protein hydrolysates as well as CH and SH enriched biscuits (CHB and SHB) on post-prandial glucose 
response in vitro. 
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2.Material and methods 
2.1 Protein hydrolysates  
Food-grade protein hydrolysates from bovine casein (CH) and soy isolate (SH), were donated by A. 
Costantino & C (Italy).  Nutritional facts for each hydrolysate is provided in Table 1. 
Table 1. Casein and soy protein hydrolysate composition  
(g/100g) Casein (CH)  Soy (SH) 
Protein  82,9 86,4 
Carbohydrate 8.1 3.0 
Total Fats ND 4.3 
Of which saturated ND 21.8% 
Fibers 0.7 1.1 
Sugars ND ND 
Salt 3.5 4.9 
Energy Value (kcal/ kJ) 374/1588 388/1642  
pH (2%m/v) 5,9 5,5 
Loss on drying (%) 4,4 3,7 
 
 
2.2 Model biscuits design 
Control biscuits (ConB) without protein hydrolysates and two types of CH and SH-enriched biscuits 
providing 4.5% (CHB1 and SHB1) and 13% (CHB2 and SHB2) of each hydrolysate were developed. 
The lower percentage hydrolysate formulations (4.5% CH/SH) refer to biscuits that comply with the 
claim of “source of protein” (at least 12% of the energy comes from protein), and the biscuits with a 
higher percentage of hydrolysate (13% CH/SH) comply with the “high protein” claim (at least 20% 
of the energy comes from protein) according to the European Food Safety Authority (EFSA 
Commission, 2012). 
Model biscuits were prepared according to the formulations proposed by Kong et al., (2016). For the 
preparation of the model biscuit: flour 00’ (Divella S.p.A, Italy), bottled still water, baking powder 
(Lievito dolci Paneangeli, Cameo S.p.A) and sugar (Eridania Italia S.p.A) were used.  
CH and SH-enriched biscuit were prepared adding CH and SH respectively in different amount. The 
formulations are shown in Table 2, whereas Table 3 shows the final nutritional content of the ConB, 
4.5% CH and SH-enriched biscuits (CHB1, SHB1) and 13% CH and SH- enriched biscuits (CHB2, 
SHB2). 
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Table 2. Hydrolysate-enriched biscuit (4.5% and 13%) and control biscuit (ConB) recipe 
 
Ingredients (g) 
4.5% 
Hydrolysate 
13% 
Hydrolysate 
ConB 
Flour 68.0 58.4 73.1 
Hydrolysate 5.1 14.7 - 
Sugar 21.9 21.9 21.9 
Water 17.5 17.5 17.5 
Baking powder 0.6 0.6 0.6 
 
Table 3. Nutritional content of the ConB, 4.5% CH and SH-enriched biscuits (CHB1, SHB1) and 
13% CH and SH- enriched biscuits (CHB2, SHB2). 
100 g CHB1 CHB2 SHB1 SHB2 ConB 
Energy (kcal) 387.2 382.4 392.3 392.3 382.2 
Protein (g) 12.7 20.0 13.1 20.9 8.7 
Fat (g) 0.9 0.8 1.2 1.5 1.0 
Saturated fats (g) 0.2 0.1 0.2 0.3 0.2 
Carbohydrate (g) 79.2 71.1 79.8 71.3 83.1 
Fibers (g) 2.2 1.4 2.5 1.2 3.2 
Sugars (g) 24.0 23.6 24.3 24.0 24.1 
Starch 53.0 46.1 53.0 46.1 55.8 
Sodium (mg) 280 640 361 872 84 
%Energy from protein 13.12 20.92 13.34 21.30 8.99 
 
The biscuits were prepared at a laboratory scale, and baked using a small/pilot scale convection 
baking oven. According to the method after the dough preparation it was kneaded for 10 minutes, 
then a sheet of 2 mm thickness and 3.5 cm diameter with a rolling pin was formed and circular biscuits 
cut using a cookie cutter. Biscuits were baked at 190° C for 15 min in a convection oven. After this, 
they were cooled, processed into powder using a food processor and stored for further analysis. 
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2.4 Simulated gastrointestinal digestion 
In vitro gastrointestinal digestion was performed with 5 g of each CHB1, SHB1, CHB2, SHB2, ConB 
respectively, according to Minekus et al., (2014). Each sample was prepared in 50 ml falcon tubes, 
digested in triplicates together with a blank of digestion (sample including all digestion fluids without 
biscuit). Samples were incubated in a shaking water bath at 37°C at 100 rpm, in dark conditions. At 
intestinal phase, an aliquot from each sample was collected (digesta), centrifuged at 21100 g for 10 
min at 4°C and then freeze dried. Samples were stored at -25°C until further analysis. 
For the simulated gastrointestinal digestion (SGID), the following reagents were used: α-amylase 
(from porcine pancreas, ≥10 U/mg solid, Sigma Aldrich), pepsin (from porcine gastric mucosa ≥250 
U/mg, Sigma Aldrich), bile salts (Sigma Aldrich), pancreatin (from porcine pancreas, 4 X USP, 
Sigma Aldrich).  
 
2.5 DPP-IV inhibition assay 
CH and SH were reconstituted in 100 mM Tris-HCl buffer, pH 8.0, at initial concentrations ranging 
from 0.25 to 25 mg/ml, as well as the freeze-dried digesta of each biscuit, considering the initial 
protein content of the biscuits per ml of digesta. 
The DPP-IV inhibition assay was carried out as described by Lacroix & Li-Chan, (2013). Briefly, 25 
μL of test sample was pre-incubated with 25 μL of substrate Gly-Pro-p-nitroanilide (Gly-Pro-pNA, 
Sigma-Aldrich) 12 mM at 37 °C for 10 min, in a low-binding 96-well plate (Greiner, clear polystyrene 
wells flat bottom, Sigma-Aldrich). Then, 50 μL of DPP-IV (0.02 units/ml, from porcine kidney, 
Sigma-Aldrich) was added, followed by an incubation at 37 °C for 30 min. The enzymatic reaction 
was stopped by the addition of 100 μl of 1M sodium acetate buffer (Sigma-Aldrich) pH 4.0. 
The absorbance of the released pNA was measured at 405 nm using a microplate reader (Multiskan 
GO, Thermo Fisher Scientific). The negative control contained 100 mM Tris–HCl buffer pH 8.0 and 
the reaction substrate Gly-Pro-pNA, whereas Diprotin A (Enzo Life), competitive inhibitor of DPP-
IV, was used as a positive control. Each test sample and both positive and negative control were 
analyzed in triplicate. 
The percentage of DPP-IV inhibition was defined as the percentage of DPP-IV activity inhibited by 
a given concentration of hydrolysate (protein basis) and was calculated using the absorbance values 
corrected with blanks (Tris-HCl buffer only). 
DPP-IV IC50 values (concentrations of hydrolysate/digesta required to cause a 50% inhibition of the 
enzyme activity) were determined by plotting the percentage of inhibition as a function of the 
concentration of test compound.  
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Lineweaver–Burk analysis was used to study the mode of inhibition according to Nongonierma & 
FitzGerald, (2013).The initial rate of the reaction (pNA released from Gly-Pro-pNA) was measured 
at different Gly-Pro-pNA concentrations ranging between 0.2 and 0.6 mM in the presence and 
absence of the DPP-IV peptide inhibitors at their IC50 concentration.  
2.6 Glycemic index determination 
The glycemic index (GI) determination was performed according to Kim & White (2012) and the 
following reagents were used: pancreatin (EC 232.468.9, from porcine pancreas, activity 4 × USP/g, 
Sigma-Aldrich), amyloglucosidase (EC 3.2.1.3, 3300 U/ml, Megazyme total starch kit), glucose 
oxidase/peroxidase reagent (Sigma Aldrich), o-dianisidine dichloride (Sigma Aldrich), anhydrous 
glucose (Carlo Erba) and absolute ethanol (Merck). The enzyme solution for digestion was prepared 
as follows: 1.8 g of pancreatin was dispersed in 4 mL of distilled water and centrifuged at 310 g for 
10min. The supernatant was mixed with 1.6 mL of diluted amyloglucosidase (1.28 mL of 
amyloglucosidase., 3300 U/mL, diluted to 1.6 mL of distilled water), and distilled water (400 ul) was 
added until a final volume of 5 mL.  
All biscuit sample processed into powder and a control (white bread made from wheat flour) were 
weighed to 100 mg into 50 mL tubes, in triplicate, with 10 glass beads (5 mm diameter) added to each 
tube. A solution containing 2 ml of 0.05 M hydrochloric acid and 10 mg of pepsin was added to each 
tube and incubated at 37 °C in a shaking water bath for 30 min. Then, 4 ml of sodium acetate buffer 
(0.5 M, pH 5.2) was added to each tube; the freshly prepared enzyme solution (1 mL) was added after 
1 min intervals. The mixtures were then incubated at 37 °C in a shaking water bath. Aliquots (100 μl) 
were taken at 0, 30, 60, 90, 120, and 180 min intervals and mixed with 50% ethanol (1 ml). 
The samples were centrifuged at 21100 g for 10 min, and the hydrolyzed glucose content of the 
supernatant was measured by using the glucose oxidase-peroxidase assay. Total starch hydrolysis (%) 
was calculated and the GI was then estimated by using the following equation according to Goñi, 
Garcia-Alonso, & Saura-Calixto, (1997):  
GI = 39.71 + 0.549HI. 
The area under the curve (AUC) is calculated for each interval of sampling during the digestion part 
of the assay. Then, the total AUC is calculated for each sample and then the hydrolysis index (HI) is 
estimated as follow: 
HI = AUC (sample) / AUC (reference control) 
For the glucose determination in the GI digestion samples, the protocol established by Sigma Aldrich 
in its Glucose Assay Kit was followed.  
All analyses were done in triplicate.  
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The absorbance of each tube against a reagent blank at 540 nm and the glucose was calculated by 
preparing a standard curve containing glucose from 10 to 100 ug/ml. According Goñi et al., (1997), 
to transform the glucose into starch, a factor of 0.9 was used. 
 
2.7 Statistical analysis 
Data about IC50 and Lineweaver–Burk were evaluated for differences by two-way repeated measures 
analysis of variance (ANOVA). 
Data on the replicate preparations of GI were analyzed by using the analysis of variance (ANOVA). 
When appropriate, differences between means were tested using the Student's t-test. 
Statistical analysis of data was carried out using SPSS (version 21, SPSS Inc. Chicago, IL, USA). 
Statistical significance was set at a level of α =0.05 (5%). 
 
3. Result 
 
3.1 Mode of inhibition of DPP-IV  
The inhibition of the enzyme activity of DPP-IV by CH and SH was evaluated. For each hydrolysate 
tested, the IC50 value was used as criteria to compare the effectiveness of the inhibition of each 
sample. Data showed that CH has an IC50 of 2.59 mg/ml whereas SH displayed an IC50 of 3.56 mg/ml 
(Table 4). The lower IC50 is, the more effective the hydrolysate is in inhibiting the enzyme, since this 
means that less concentration of hydrolysate is required to achieve the inhibition. In this frame, CH 
is more effective ingredient in terms of inhibition. 
In order to look into the type of inhibition presented by CH and SH, a Lineweaver-Burk model assay 
was evaluated for both. Included in this test was DiProtin A, which is used as a reference for 
competitive inhibition (Table 4).  
Data showed that either way CH and SH are able to inhibit the activity of DPP-IV; particularly SH 
acts in a competitive manner whilst CH behaved as mixed/not competitive inhibitor (p<0.05). 
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Table 4. IC50 value (mean±standard deviation) and mode of inhibition* (p<0.05) of CH and SH 
estimated by Lineweaver–Burk plot. Diprotin A was used as competitive inhibitor of DPP-IV. 
 
 
 
 
 
 
The samples of biscuit were digested and the extractable digesta fraction was separated and analyzed 
for its inhibitory activity against DPP-IV. 
No significant difference between digested biscuits (CHB1, SHB1, CHB2, SHB2, ConB) for the 
inhibition of DPP-IV activity was observed (p>0.05), probably due to more factors of the food matrix 
that interfered, decreasing the inhibitory activity.  
 
3.2 GI determination 
Data from GI determination showed that the GI of all the biscuits was lower than white bread, which 
is represented as a reference with an index of 100 (Figure 1). Only SHB2 showed significantly lower 
GI than the others (p<0.05). According to GI data, when the percentage of protein was higher, the GI 
was lower, and it confirmed that the soy hydrolysate biscuits had lower GI than the casein ones.  
From these results, it can be concluded that the soy hydrolysate-enriched biscuits generated a lower 
GI probably due to a higher protein content. Of note, SH had a slightly higher protein content in 
comparison to the 13% casein hydrolysate biscuit because of the weight loss of baking and freeze 
drying (17.3% and 16.3%, respectively). This might have caused the difference with respect to the 
casein 13% biscuit.  
Furthermore, CHB2 (but not CHB1) differed from the ConB. The biscuits containing the lower 
amount of hydrolysates had a higher carbohydrate percentage, that was mainly composed of sugars 
and starch (and a small amount of fibers), that are the source of the glucose measured in the GI index 
assay. Thus it could be expected that the higher their content is, the higher is the in vitro GI of the 
food product.  
In general, the biscuits with 4.5% hydrolysate did not contain significantly less carbohydrates than 
the control biscuits, and in turn the ~13% formulations had almost 10% less carbohydrates. 
Together with the results from the GI analysis, it can be highlighted that the highest soy formulation 
gave a lower GI out of all the samples tested  
 IC50 ±SD (mg/ml) Mode of inhibition  
CH 2.59±0.34 *Mixed/not competitive 
SH 3.56±0.42 *Competitive 
Diprotin A 0.02±0.01 *Competitive 
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Figure 3. in vitro glycaemic index (GI) of biscuit samples. Statistical differences are denoted as * 
(p<0.05). White bread was used as positive control of the assay. 
 
4. Discussion 
While the production of DPP-IV inhibitors from dietary proteins and the identification of active 
peptide sequences have been the subject of a large body of research, little is currently known on the 
bioavailability of these bioactive molecules, involved in glycaemia control (Dailey & Moran 2013).  
GLP-1 is one of the most relevant molecular targets for the prevention and treatment of diabetes. 
There has been increasing interest in the possible ability of dietary factors to treat diabetes modulating 
the secretion of endogenous GLP-1(Tsuda 2015). 
Several studies showed that amino acids such as glutamine and arginine are able to inhibit DPP-IV 
enzyme (Samocha-Bonet et al., 2011, Clemmensen et al., 2013, Greenfield et al., 2009). Glutamine 
is also reported to increase the concentrations of GLP-1, GIP, and insulin in humans (Samocha-Bonet 
et al., 2011, Clemmensen et al., 2013, Greenfield et al., 2009). Furthermore, GLP-1 secretion is also 
stimulated by branched-chain amino acids, including leucine and isoleucine, in NCI-H716 cells (Chen 
& Reimer 2009). Moreover, GLP-1 secretion is enhanced by skim milk and casein but not by whey 
(Chen & Reimer 2009); proteins from codfish, egg, and wheat, as well as egg protein hydrolysate can 
trigger GLP-1 release (Geraedts et al., 2011). Pioneering research on protein hydrolysates reported 
the GLP-1 secretion-enhancing effect and hyperglycemia-suppressing effect of the hydrolysate of 
zein, a maize-derived protein (Higuchi et al., 2013). 
Fractionation of DPP-IV-inhibiting protein hydrolysates and digests and analysis of the most potent 
fractions by mass spectrometry have allowed the identification of a number of peptide sequences 
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contributing to the observed inhibitory activity, that vary widely in terms of their length (2-17 amino 
acids long), amino acid composition and potency (half-maximal inhibitory concentration (IC50) 
values ranging from 5 μM to >20 000 μM.  
Similar to the hydrolysates whose IC50 values ranged from μg/mL to mg/mL the identified DPP-IV 
inhibitory peptides show much weaker effect on DPP-IV activity than the synthetic DPP-IV inhibitors 
currently used for the treatment of type 2 diabetes (IC50 in the nM range) (Hunziker, Henning, & 
Peters, 2005).  
Accordingly, casein hydrolysate used in this study showed a lower IC50 value of 2.59 mg/ml than 
soy protein hydrolysate with IC50 of 3.56 mg/ml. This might indicate that the casein hydrolysate has 
a BAPs/ amino acids profile that is more efficient in the inhibition of DPP-IV. 
These BAPs can be found in the sequences of commonly consumed proteins such as those from milk 
and soy, and were shown to inhibit the DPP-IV enzyme; particularly the tripeptide IPI (also known 
as diprotin A), which can be found in the sequence of k-casein, is a well-known DPP-IV inhibitor and 
the most potent (IC50 = ~4 μM) of currently known peptides.  
The consumption of specific food products, including dairy proteins, has been reported in a number 
of epidemiological and observational studies to be associated with a reduced incidence of type 2 
diabetes linked to the ability of the relative BAPs involved in blood glucose metabolism and/or to 
stimulate the secretion of gut-derived hormones (Lacroix & Li-Chan 2014b) 
At this regard, exhaustive studies conducted in rodents and humans have demonstrated that high 
protein (HP) diets improve glucose homeostasis. Particularly, increased HP intake over several 
weeks improves metabolic parameters, including body weight, adiposity, insulin sensitivity, 
glycated hemoglobin levels, and food intake in both humans and rodents (Arciero 2008, Lacroix 
2004; Pichon 2006). Five weeks of HP feeding in diabetic patients improved glucose tolerance 
even when individuals maintained a stable weight (Gannon  et al., 2003) and pair-feeding to match 
energy intake and body weight improved glucose homeostasis in rats fed a HP diet  (Blouet et al., 
2006). This suggests that HP diets regulate glucose homeostasis independent from effects on food 
intake and/or body composition. Notably, acute HP feeding is also effective at lowering blood 
glucose levels and improving glycemic control in individuals with diabetes (Nuttal et al., 1984, 
Manders et al., 2005). It has been postulated that these improvements in glucose control result 
from decreased dietary carbohydrate content; however, the addition of protein to a meal reduces 
the post-prandial glucose response compared to a meal consisting of equal carbohydrate content 
alone (Claessens et al., 2009; Nuttal et al., 1984) and consumption of a pre-meal protein beverage 
reduces post-meal glycemia (Gunnerud et al., 2012). This suggests that the glucoregulatory 
influence of acute HP intake results from the presence of protein itself. Clinical studies have shown 
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that dietary protein intake or intestinal protein administration increases circulating levels of gut 
peptides, including cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), and peptide YY 
(PYY) (van der Klaauw et al., 2013)  
The binding of many foods-derived peptides with competitive DPP-IV inhibitors has been described 
at the active site of DPP-IV, mainly through interactions with a hydrophobic pocket in the enzyme. 
However, a secondary binding site for DPP-IV inhibitors has also been described, located close to 
the active site and results in a mixed-type inhibition of DPP-IV (Lacroix & Li-Chan, 2016). For 
example, a milk protein-derived dipeptide Trp-Val behaved as a non-competitive inhibitor of DPP-
IV as well as several milk derived-peptides showed no competitive or mixed type of inhibition near 
the active site of DPP-IV (Nongonierma & FitzGerald, 2013). This might have been the case for the 
CH tested in this study, since it did not clearly act as a competitive inhibitor of the enzyme. When 
evaluating the mode of inhibition of the raw hydrolysates, SH presented a type of inhibition more 
similar to that of a competitive inhibitor whereas Casein seemed to have a mixed/noncompetitive type 
of inhibition. This again can be attributed to differences in the peptide profile and specific sequences 
present in the two types of hydrolysates, since they come from different protein sources. 
It is known that bioactive peptides are produced from proteins by fermentation of food using 
proteolytic starter cultures, during the manufacture of protein hydrolysates, during in vivo digestion 
of dietary proteins, or during in vitro digestion, using various proteolytic enzymes (Capriotti et al., 
2015). Regarding the changes they might undergo during digestion, although some of the peptides 
with inhibitory activity may reach the small intestine unchanged, it is likely that many of the peptides 
identified to have in vitro DPP-IV inhibitory activity will be broken down in vivo during the digestion 
process (Lacroix & Li-Chan, 2016). Even though it was possible to observe an inhibition of the 
original hydrolysates when tested directly in the presence of DPP-IV, there are other phenomena that 
can occur to the peptides present in the raw material such as the processing to prepare the biscuits 
(sugar-amino acid interactions during baking process) and the simulated digestion with a series of 
gastric enzymes that can affect not only their structure but also their availability.  
The possible causes of a GI lowering effect of proteins in a carbohydrate containing foods can be : 
an increase in viscosity of the digesta (that negatively affects enzymatic action and mobility of 
solutes), an increase in digested solids, the presence of hypo-glycaemic phytochemicals and, the 
increased protein percentage with respect to a non-protein containing version (Dove et al., 2011).  
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Finally, it can be hypothesized that the biscuits developed in this study have a potential to eventually 
be a type of food product that can deliver a benefit in the maintenance of glucose homeostasis and 
other related mechanisms. 
In this study, there was no significant difference between IC50 of the digested biscuit, indicating that 
when used in a food matrix and digested, the hydrolysates might vary their initial capacity to inhibit 
DPP-IV. The glycaemic index (GI) of the biscuits shows that the biscuit formulation that had more 
clear decrease in the GI was the biscuit containing soy at 13% hydrolysate. This shows that the 
addition of proteins in a biscuit formulation in a higher percentage (13% or possibly more) can 
potentially decrease the GI of the biscuit and with this generate a food product that can possibly 
contribute to a lower peak in postprandial glycaemia.  
It is important to evaluate not only the potential health benefit of a food ingredient but also try to 
confirm its potential effect after it has been incorporated into a food matrix.  
 
5. Conclusion 
This study tested CH and SH as functional ingredients for glycaemia control, through inhibition 
of DPP-IV activity.  
Data showed that when included in a food matrix these ingredients loosed their inhibitory activity 
against DPP-IV. This finding might be due to a food matrix effect, i.e. to other components present 
in the food that could hide the bioactivity of CH and SH at the doses used in the biscuits.   
A higher amount of CH and SH in the biscuits may be necessary to trigger a reduction of DPP-IV 
activity and a potential effect in glucose homeostasis.  
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Gut-brain axis is a crucial hub of the food intake and energy balance regulation. 
Dichotomy between homeostatic and non-homeostatic/hedonic systems should be replaced by a 
larger, highly interactive system that unifies homeostasis with reward, cognition, and emotion.  
Understanding the integrative role of the CNS in energy and reward homeostasis has become 
increasingly important considering the prevalence of obesity and functional gastrointestinal disorders 
(FGIDs). The GIT is the largest endocrine organ in the human body and it represents the gateway for 
communication between the human body and the external environment. Distress (i.e. inflammation) 
or adaptations in the communication of sensory information may contribute to the development or 
maintenance of disease. Several diseases such as celiac disease, Crohn’s disease, type 1 diabetes and 
some food allergies, are known to increase the GIT mucosa permeation of macromolecules. 
As reported in Chapter 2 FGIDs are classified as morphologic and physiological abnormalities often 
occurring in combination with motility disturbance, visceral hypersensitivity, as well as altered 
mucosa, immune function, gut microbiota and CNS processes. The incidence of FGIDs among 
population is about 11%. Some of the symptoms reported for the functional dyspepsia are similar to 
those of non-celiac gluten sensitivity such as postprandial fullness, early satiety, epigastric pain, and 
epigastric burning. These symptoms may appear isolated or combined after consumption of specific 
foods. The nutritional consequence of this symptomatology is that people arbitrarily exclude from 
diet the foods which are mainly associated with the symptoms such as spicy foods, high-fat meals, 
dairy products or cereal-based foods. Life-lasting dietary exclusions may cause nutritional deficiency 
as well as metabolic adaptation that may be even worst of the previous symptomatology. This is the 
reason why in the case of a specific food/nutrient-induced disorder the usual dietetic approach is the 
exclusion from the diet of the specific food/nutrient for a certain period and a slow re-introduction in 
the follow-up period.  
The exclusion from the diet of gluten represents the cure only for people with celiac disease but 
literature was still lacking on the knowledge of the metabolic response to a gluten-free meal in patients 
with celiac disease compared to healthy subjects. The human study reported in Chapter 3 aimed at 
filling that gap of knowledge. From a dietetic perspective, the effect of a meal is more relevant in 
exerting metabolic responses than a single nutrient/food. Celiac subjects (CD) at the diagnosis or on 
a gluten free diet since 12 months and healthy subjects consumed a standard gluten-free meal and the 
post-prandial blood glucose and hormone response as well as appetite feelings were monitored. The 
main results of the study was that CD showed a lower postprandial blood glucose response than 
healthy subjects with a lower response of GLP-1, GIP and insulin. The different hormonal status was 
associated with a different evolution of the post-prandial hunger sensation that was higher in CD at 
diagnosis than in the others. These findings suggested that CD subjects after more than 1 year on a 
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gluten free diet did not recover a complete functionality of the intestine and this might determine an 
adaptive hormone postprandial response that may influence post-prandial appetite sensations and 
insulin resistance over long period. 
From a food science and nutrition perspective, some bioactive compounds are present in foods and 
may be effective in the control of appetite, intestinal inflammation and glycaemia. In this thesis the 
potential of food bioactive peptides contained in milk proteins, casein and soy hydrolysates towards 
appetite, inflammation and glycaemia was tested and described in the human study in Chapter 4, and 
in in vitro studies of Chapter 5 and 6, respectively. 
In Chapter 4 two beverages, one enriched with milk proteins and one with carbohydrates (control) 
were developed and a human study with women consuming the beverage after an exercise session 
was carried out aiming at evaluating the effect of the beverages on the energy intake at the subsequent 
dinner. Data showed that the milk protein-enriched beverage was able to influence hunger sensation 
and reduce energy intake at subsequent meal only in women having a strong cognitive control of 
eating behaviour. 
In Chapter 5 casein and soy hydrolysates were tested in Caco-2 cells cultivated in a normal condition 
and in the presence of TNF-α to induce intestinal inflammation. Data showed that digested casein and 
soy protein hydrolysates positively influenced cells viability, particularly in inflamed condition. Data 
about monolayer integrity (TEER) showed an absence of irreversible damage at the normal and 
inflamed cell monolayer when it was treated with digested samples.  
In Chapter 6 casein (CH) and soy (SH) protein hydrolysates were tested as functional ingredients 
for glycaemia control, through inhibition of Dipeptidyl peptidase-IV (DPP-IV) activity. This study 
showed that when used in a model food CH and SH loosed their inhibitory activity against DPP-
IV possibly because of other food components that could hide the bioactivity of CH and SH at the 
doses used in the model food.  
 
All in all, the findings of this thesis showed that: 
- Despite the attention and the knowledge on dietary factors influencing etiology and 
symptomatology of FGIDs is increased, there is a need of large nutrition surveys with a 
prospective design in order to provide information on dietary habits of FGID subjects and 
clarify whether dietary preferences reflect the subconscious exclusion of foods to which 
subjects are intolerant. 
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- Celiac subjects after more than 1 year on a gluten free diet did not recover a complete 
functionality of the intestine and this might determine an adaptive hormone postprandial 
response that could influence appetite sensations and insulin resistance over long period. 
- A functional beverage enriched with milk proteins could modify daily eating habits by 
enhancing satiety in women with a stronger cognitive control of eating behaviour.   
- Simulated gastrointestinal digestion of the dietary protein hydrolysates increases the 
bioaccessibility of bioactive peptides and amino acids, enhancing the chance of these 
compounds to be absorbed and to exert a biological effect, regulating the intestinal epithelial 
barrier structure and functions and restoring the properties (and functions) of intestinal 
epithelial cells. 
- Casein (CH) and soy hydrolysates (SH) may be functional ingredients for glycaemia control 
through inhibition of DPP-IV activity. A food matrix effect could hide the bioactivity of those 
ingredients at the doses used in the biscuits during in vitro enzymatic digestion. In vivo studies 
are necessary to evaluate the effectiveness of CH and SH-enriched food for glycaemia control. 
 
This scenario highlights the importance of validation of efficacy of new foods/whole meals both in 
vitro to assess the potential functionalities before performing human studies as well as in vivo in a 
well-characterized population. Indeed, growing evidence shows that the effect of food on wellness 
and dietary behaviour may be also influenced by psychological attitude of people as well as by gut 
microbiota reactivity to a food/diet. 
In the context of new foods/diets to tackle obesity and FGIDs the gut-brain interconnection is central 
and should be better targeted both at the step of the food design and validation. 
 
